

## CURRICULUM VITAE

### A. BIOGRAPHICAL INFORMATION

Erin Janelle Aiello Bowles, MPH  
Kaiser Permanente Washington Health  
Research Institute\*  
Kaiser Foundation Health Plan of Washington  
1730 Minor Ave Suite 1600  
Seattle, WA 98101

Phone: (206)-287-2708  
Fax: (206)-287-2485  
Email: [erin.a.bowles@kp.org](mailto:erin.a.bowles@kp.org)

### B. EDUCATION

University of Washington, Seattle, WA. MPH, Epidemiology, 2000-2002.  
University of California, Irvine, CA. BS, Applied Ecology, *magna cum laude*, 1996-2000.

### C. PROFESSIONAL POSITIONS

Director, Collaborative Science Division, Kaiser Permanente Washington Health Research Institute,  
Kaiser Foundation Health Plan of Washington\*, 2024-present  
Manager, Collaborative Science Division, Kaiser Permanente Washington Health Research Institute,  
Kaiser Foundation Health Plan of Washington\*, 2022-2024  
Research Associate IV and supervisor, Kaiser Permanente Washington Health Research Institute, Kaiser  
Foundation Health Plan of Washington\*, 2017-2022  
Research Associate III, Kaiser Permanente Washington Health Research Institute, Kaiser Foundation  
Health Plan of Washington\*, 2010-2017  
Research Associate II, Group Health Research Institute,\* 2005-2010  
Research Associate I, Group Health Research Institute,\* 2002-2005  
Data Coordinator IV, Fred Hutchinson Cancer Research Center, 2002-2003  
Research Assistant, Fred Hutchinson Cancer Research Center, 2000-2002  
Intern, Breast and Cervical Health Program (BCHP), Public Health – Seattle & King County, 2001  
Research Assistant at the Center for Occupational and Environmental Health, University of California,  
Irvine, 1999-2000

### D. PROFESSIONAL HONORS

Kaiser Permanente Learning University Activate Leadership program graduate, 2021  
Exceptional Reviewer for *Medical Care*, 2007  
Second Place Poster Award, Society for Epidemiologic Research, 2007  
First Place Poster Award, HMO Research Network Conference, 2007  
Exceptional Reviewer for *Medical Care*, 2006  
Best Poster Award (1<sup>st</sup> place), American Society of Preventive Oncology, 2006.  
Best Poster Award (3<sup>rd</sup> place), American Society of Preventive Oncology, 2005.  
Student-Postdoc Advisory Committee travel award, Fred Hutchinson Cancer Research Center, 2002.

### E. MEMBERSHIPS

American Society for Preventive Oncology, 2003 – present  
Society for Epidemiological Research, 2007 – present  
F1000 faculty member, 2010 – 2017

### F. ORGANIZATIONAL SERVICE

Research Integrity Committee, Kaiser Permanente Washington Health Research Institute, 2024-present  
Promotions Committee, Kaiser Permanente Washington Health Research Institute, 2022-present

*\*Kaiser Permanente acquired Group Health in February 2017, at which point Group Health Research Institute became Kaiser Permanente Washington Health Research Institute.*

Hiring Committee, Investigative Sciences Division Director, Kaiser Permanente Washington Health Research Institute, 2024-2025  
Hiring Manager, Qualitative Research Associate Search Committee, Kaiser Permanente Washington Health Research Institute, 2021  
Hiring Manager, ACT Research Associate Search Committee, Kaiser Permanente Washington Health Research Institute, 2021-2022  
Chair and Hiring Manager, Pain/Addictions Research Associate Search Committee, Kaiser Permanente Washington Health Research Institute, 2020  
Executive Director Academic Search Committee, Kaiser Permanente Washington, 2019  
Co-lead, Epidemiology 101, Kaiser Permanente Health Research Institute, 2019  
Breast Cancer Screening Guidelines Implementation Committee, Kaiser Permanente Washington, 2017  
Cancer Researchers Group Lead, Kaiser Permanente Washington Health Research Institute, 2017-2021  
Programmer Supervisor Hiring Committee, Group Health Research Institute, 2015-16  
Instructor, Epidemiology 101, Group Health Research Institute, 2015  
Partnership for Innovation committee, Group Health Research Institute, 2010-2014  
Cancer Researchers Group chair, Group Health Research Institute, 2010-2013  
Produce Group Health Radiology Report for mammographers, Group Health, 2003-2013  
Promotions review committee, Group Health Research Institute, 2011  
Faculty advisor group to Survey, Group Health Research Institute, 2009  
Faculty Development working group, Group Health Research Institute, 2009  
Faculty Review working group, Group Health Research Institute, 2009  
Strategic Direction Setting Committee, Group Health Research Institute, 2008-2009.  
Scientific Policy Committee, Group Health Research Institute, 2007-2010. (Chair, 2008-2009)  
Instructor, Epidemiology 101, Group Health Research Institute, 2007  
Chaired working group to revise Breast Cancer Screening Program Survey, Group Health, 2006  
Faculty retreat planning committee, Group Health Research Institute, 2005  
Chaired working group to revise Breast Cancer Screening Program Survey, Group Health, 2004

#### **E. OTHER PROFESSIONAL SERVICE**

Society for Epidemiological Research Communications Committee Co-Chair (2025-present)  
Society for Epidemiological Research Communications Committee Member (2024-present)  
Science Ambassador Scholarship Judge (2022-present)  
Society for Epidemiological Research Membership Committee Co-chair (2019-2022)  
Society for Epidemiological Research Membership Committee Member (2016-2018)  
Lake Washington Institute of Technology, Bachelor's in Public Health Advisory Board – 2013-2021  
Junior Investigator Session Planning Committee, American Society of Preventive Oncology, 2006-2008

#### **F. SPECIAL NATIONAL RESPONSIBILITIES**

##### Grant Reviews

Cancer Research UK – 2018-2019  
Susan G Komen Puget Sound– 2013-2014  
Patient Centered Outcomes Research Institute– 2013  
ITHS Community Pilots - 2010 – 2012

#### **G. EDITORIAL RESPONSIBILITIES**

Editorial Boards: PLOS ONE (Academic Editor, 2017-2025)

##### Manuscript Reviewer

*Alzheimer's and Dementia*  
*American Journal of Preventive Medicine*  
*Annals of Oncology*

*BMC Cancer*  
*Breast Cancer Research*  
*Breast Cancer Research and Treatment*

*British Journal of Cancer*  
*Cancer Causes & Control*  
*Cancer Detection and Prevention*  
*Cancer Epidemiology, Biomarkers and Prevention*  
*Cancer Research*  
*Clinical Journal of Oncology Nursing*  
*Epidemiology*  
*European Journal of Cancer Care*  
*International Journal of Cancer*  
*JAMA Oncology*  
*JAMA Internal Medicine*

*Journal of Cancer Epidemiology*  
*Journal of Clinical Epidemiology*  
*Journal of Clinical Oncology*  
*Journal of General Internal Medicine*  
*Journal of the American Board of Family Medicine*  
*Journal of the American Geriatric Society*  
*Journal of the National Cancer Institute*  
*Journal of Women's Health*  
*Medical Care*  
*Preventive Medicine*  
*The Lancet Oncology*

## H. RESEARCH FUNDING

### Ongoing Research Support:

National Cancer Institute	R37CA292399 (Lowry)	9/9/2024-8/31/2029
Evaluation of Commercial Mammography-Based Artificial Intelligence Algorithms for Breast Cancer Risk Prediction in U.S. Screening Populations		
Role: Co-Investigator (10% FTE)		\$338,150 (total direct)
National Cancer Institute	R01CA282725 (Sprague)	9/19/2023-8/31/2028
Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis		
Role: Co-investigator (8% FTE)		\$421,023 (total direct)
National Cancer Institute	2P01CA154292 (Miglioretti)	9/1/2022-8/31/2027
Advancing Equitable Risk-based Breast Cancer Screening and Surveillance in Community Practice		
Role: Co-investigator (10% FTE)		\$261,178 (total direct)
National Cancer Institute	R01CA266377 (Lee)	6/1/2021 - 5/31/2026
Improving outcomes in the breast cancer screening and diagnostic continuum		
Role: Co-Investigator (10% FTE)		\$664,471 (total direct)
National Cancer Institute/Westat	75N91024F00001	3/22/2024-9/19/2026
BRCA cohort 2024 to 2025		
Role: Principal Investigator (5% FTE)		\$72,171 (total direct)

### Completed Research Support:

Centers for Disease Control and Prevention	U48DP006398 (Kessler)	9/30/2020-9/29/2025
Multi-modal Study of Validity and Reliability of Cancer Screening Questions for the NHIS		
Role: Site PI/Co-Investigator (10% FTE)		\$620,884 (total direct)
National Cancer Institute	R01CA251566 (Francis)	8/14/2020-4/30/2025
A Novel Micro-Simulation Model Approach to Estimate and Mitigate Thyroid Cancer Overdiagnosis		
Role: Site PI/Co-Investigator (10% FTE)		\$288,544 (total direct)
National Cancer Institute	R37CA222793 (Kantor)	1/1/2018 – 12/31/2024
Obesity, Chemotherapy Dosing, and Breast Cancer Outcomes		
Role: Site PI/Co-Investigator (20% FTE)		\$776,726 (total direct)
National Cancer Institute/Westat	6648-00-S018 (Bowles)	9/22/2022-3/21/2024
Breast Cancer Survivors Cohort – Radiation Summaries		
Role: Principal Investigator (5% FTE)		\$91,152 (total direct)
National Cancer Institute/Westat	6648-00-S017 (Bowles)	9/22/2022 – 9/21/2023

Randomized, Double-blind, Placebo-controlled Study of 4-hydroxytamoxifen (4-OHT) Topical Gel in Women with Mammographically Dense Breasts Role: Principal Investigator (10% FTE)		\$44,677 (total direct)
National Cancer Institute Group Health Cancer Research Program Research Specialist Award Role: Principal Investigator (10% FTE, concurrent)	R50CA211115 (Bowles)	2/1/2017-1/31/2023 \$591,513 (total direct)
National Cancer Institute Breast Cancer Survivors Cohort – Late Effects of Breast Cancer Treatments Role: Principal Investigator (10% FTE)	75N91020P00327 (Bowles)	4/1/2020-9/20/2022 \$154,797 (total direct)
National Cancer Institute Risk-based Breast Cancer Screening and Surveillance in Community Practice Role: Co-investigator (15% FTE)	2P01CA154292 (Miglioretti)	7/1/2017-11/30/2022 \$1,302,816 (total direct)
National Cancer Institute Risk of Pediatric and Adolescent Cancer Associated with Medical Imaging (RIC) Role: Site PI/Co-Investigator	R01CA185687 (Smith-Bindman)	3/1/2015-5/31/2021
National Cancer Institute Applying Breast Density to Risk Counseling (ENGAGED II) Role: Co-Investigator	R01CA190221 (O'Neill)	8/7/2015-7/31/2020
National Institute on Aging Alzheimer's Disease Patient Registry (ADPR/ACT) Role: Co-Investigator	U01 AG006781 (Larson)	5/1/2015-4/30/2020
National Institute on Aging The ACT Annual Symposium: A Living, Learning National Collaboratory to Advance Alzheimer's Disease and Brain Aging Research Role: Site PI/Co-Investigator	R13AG057087 (Larson)	5/12/2017-4/30/2020
National Cancer Institute Mammographic breast density and risk of contralateral breast cancer in Kaiser Permanente Washington Health Research Institute. Role: Co-Investigator	75N91019P00245 (Buist)	5/20/2019-5/19/2020
National Cancer Institute Mammographic Breast Density and Contralateral Breast Cancer Risk: Digitization and Assessment of Mammograms from Kaiser Colorado (KPCO Density) Role: Principal Investigator	HHSN261201700695P (Bowles)	9/20/2017-3/18/2019
National Cancer Institute Risk of New Malignancies Following Breast Cancer (Kaiser Breast Cancer Survivor Cohort) Role: Co-Investigator	HHSN261201700564P (Buist)	9/11/2017-9/10/2018
AHRQ Evidence Based Practice Center – Screening for Pancreatic Cancer Review Role: Co-Investigator	HHSA-290-2015-00007I (Lin)	9/11/2017-6/30/2019
National Cancer Institute Commonly Used Medications and Risk of Colorectal Cancer Recurrence (RECORD) Role: Co-Investigator	R01CA172073 (Chubak)	9/13/2013-7/31/2018

National Cancer Institute Risk-based Breast Cancer Screening in Community Settings Role: Co-investigator	1P01CA154292 (Miglioretti)	9/13/2011-8/31/2017
AHRQ Evidence Based Practice Center Role: Research Associate	HHSA-290-2012-00151-I (Lin)	3/1/2013-8/31/2017
National Cancer Institute/Westat Lobular Duct Involution and Breast Density Role: Principal Investigator	6182-S13-Mod 1	5/11/2015-8/31/2016
National Cancer Institute Breast Cancer Surveillance Consortium Research Resource Role: Associate Director	HHSN261201100031C (O'Meara)	8/1/2011-7/31/2016
Branta Foundation Medication Exposure and Cognitive Decline in Older People Role: Research Associate	None (Dublin)	8/1/2012-7/31/2015
National Cancer Institute CRN Clinical Communication Research Center: Testing an Optimal Model of Patient-Centered Cancer Care Role: Research Associate	1P20CA137219 (Dearing)	9/30/2008-8/31/2014
American Cancer Society Effectiveness of Health Care System Outreach for Breast Cancer Screening Role: Co-investigator	RSGI-I 00-01-CPHPS (Buist)	7/1/2011-6/30/2014
National Cancer Institute Kaiser Tamoxifen and Mammographic Density Study Role: GH Principal Investigator	HHSN261201100441P (Bowles)	9/1/2011-3/1/2013
National Cancer Institute Commonly Used Medications and Breast Cancer Recurrence Role: Research Associate	1R01CA120562 (Boudreau)	9/1/2007-7/31/2012
National Cancer Institute Cancer Research Network Across Health Care Systems: CRN3 – Infrastructure Role: Research Associate	5U19CA079689 (Wagner)	5/1/2007-4/30/2012
National Cancer Institute Building CER Capacity: Aligning CRN, CMS, and State Resources to Map Cancer Care Role: Co-investigator	1RC2CA148185 (Weeks)	9/30/2009-8/31/2011
National Cancer Institute Breast Cancer Surveillance in a Defined Population Role: Research Associate	2U01CA063731 (Buist)	8/1/2005 – 7/31/2010
National Cancer Institute Improving breast cancer surgery quality through a collaborative surgery database Role: GH Principal Investigator	1RC1CA145402 (McCahill)	10/1/2009-9/30/2011
National Cancer Institute Understanding Variability in Community Mammography Role: Research Associate	5R01CA107623 (Elmore)	7/1/2004 – 4/30/2010

National Cancer Institute Gene Copy Number Chances and Breast Cancer Survival Role: Research Associate	5R01CA098415 (Porter)	6/1/2004-5/31/2010
AMGEN Descriptive Epidemiology and Clinical Course of Myelodysplastic Syndromes (MDS) in a Health Maintenance Organization Role: GH Principal Investigator	None (De Roos)	12/11/2006-4/30/2009
National Institutes of Health Radiologist Feedback Reports Role: GH Principal Investigator	HHSN261200700389P (Bowles)	9/12/2007-12/30/2007
National Cancer Institute Patient Centered Communication in Cancer Care Role: Research Associate	Contract-None (Wagner)	10/1/2005-1/31/2007
Department of Defense A Population-Based Randomized Trial to Assess the Effects of Short-Term Cessation of HRT on Mammography Assessments and Breast Density Role: Research Associate	DAMD17-03-1-0447 (Buist)	6/1/2003 – 6/30/2008

## I. TEACHING AND MENTORING RESPONSIBILITIES

### Teaching history

Guest lecturer, Lake Washington Institute of Technology, “Practical and real-life examples of epidemiology”, June 9, 2015  
 Guest lecturer, University of Washington MEDEX Physician Assistants training program, “Randomized Clinical Trials”, June 26, 2013  
 Guest lecturer, University of Washington MEDEX Physician Assistants training program, “Randomized Clinical Trials”, June 28, 2012  
 Teaching Assistant, Environmental Health and Quality class, University of California, Irvine, 2000.

### Advising and formal mentoring

Nicole Gatto, PhD, Principal Collaborative Scientist, KPWHRI 2022-present  
 Mala Rupan, MD, Project Manager, KPWHRI 2023-2024  
 Cameron Haas, PhD Candidate, University of Washington 2020-2022  
 Arika Wieneke, Bachelor’s Student, Whitman College, 2013-2014.  
 Sarah Lowry, PhD Candidate, University of Washington, 2010-2012.  
 Melissa Romaine, PhD Candidate, University of Washington, 2009-2011.  
 Elana Feldman, Bachelor’s Student, Oberlin, 2007-2008.  
 HeeYon Sohng, Post-doctoral Fellow, Harborview, 2007.  
 Megan Welsh, MPH Student, University of Washington, 2006-2007.  
 Anthony Crest, MPH Student, University of Washington, 2004-2005.

## J. PUBLICATIONS

### Published papers in refereed (peer-reviewed) journals

\*Primary mentor of first listed author

1. Chlebowski RT, **Aiello E**, McTiernan A. Weight Loss in Breast Cancer Patient Management. *Journal of Clinical Oncology*. 2002 Feb 15;20(4):1128-43. doi: 10.1200/JCO.2002.20.4.1128. Review. PubMed PMID: 11844838.
2. Irwin ML, Yasui Y, Ulrich CM, Bowen D, Rudolph RE, Schwartz RS, Yukawa M, **Aiello E**, Potter JD,

- McTiernan A. Effect of exercise on total and intra-abdominal body fat in postmenopausal women: A randomized controlled trial. *JAMA*. 2003 Jan 15;289(3):323-30. doi: 10.1001/jama.289.3.323. PubMed PMID: 12525233.
3. Tworoger SS, Yasui Y, Vitiello MV, Schwartz RS, Ulrich CM, **Aiello EJ**, Irwin ML, Bowen DB, Potter JD, McTiernan A. Effects of a Yearlong Moderate-Intensity Exercise and a Stretching Intervention on Sleep Quality in Postmenopausal Women. *SLEEP*. 2003 Nov 1;26(7):830-6. doi: 10.1093/sleep/26.7.830. PubMed PMID: 14655916.
  4. Tworoger SS, Chubak J, **Aiello EJ**, Yasui Y, Ulrich CM, Farin F, Potter JD, McTiernan A. Associations between CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormones in postmenopausal women. *Cancer, Epidemiology, Biomarkers, & Prevention*. 2004 Jan;13(1):94-101. doi: 10.1158/1055-9965.epi-03-0026. PubMed PMID: 14744739.
  5. Tworoger SS, Chubak J, **Aiello EJ**, Yasui Y, Ulrich CM, Farin FM, Stapleton PL, Irwin ML, Potter JD, Schwartz RS, McTiernan A. The Effect of CYP19 and COMT Polymorphisms on Exercise-Induced Fat Loss in Postmenopausal Women. *Obesity Research*. 2004 Jun;12(6):972-81. doi: 10.1038/oby.2004.119. PubMed PMID: 15229337.
  6. **Aiello EJ**, Yasui Y, Tworoger SS, Ulrich CM, Irwin ML, Bowen D, Schwartz RS, Kumai C, Potter JD, McTiernan A. Effect of a yearlong, moderate-intensity exercise intervention on the occurrence and severity of menopause symptoms in postmenopausal women. *Menopause*. 2004 Jul-Aug;11(4):382-8. doi: 10.1097/01.gme.0000113932.56832.27. PubMed PMID: 15243275.
  7. Sparks R, Ulrich CM, Bigler J, Tworoger SS, Yasui Y, Rajan KB, Porter P, Stanczyk FZ, Ballard-Barbash R, Yuan X, Gang Lin M McVarish L, **Aiello EJ**, McTiernan A. UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients. *Breast Cancer Research*. 2004;6(5):R488-98. doi: 10.1186/bcr818. Epub 2004 Jun 29. PubMed PMID: 15318931; PubMed Central PMCID: PMC549165.
  8. Frankenfeld CL, McTiernan A, **Aiello EJ**, Thomas WK, LaCroix K, Schramm J, Schwartz SM, Holt VL, Lampe JW. Mammographic density in relation to daidzein-metabolizing phenotypes in overweight, postmenopausal women. *Cancer Epidemiol Biomarkers Prev*. 2004 Jul;13(7):1156-62. PubMed PMID: 15247126.
  9. **Aiello EJ**, Buist DSM, White E, Seger D, Taplin SH. Rate of breast cancer diagnoses among postmenopausal women with self-reported breast symptoms. *Journal of the American Board of Family Practice*. 2004 Nov-Dec;17(6):408-15. doi: 10.3122/jabfm.17.6.408. PubMed PMID: 15575032.
  10. **Aiello EJ**, Buist DSM, White E, Porter P. Association between mammographic breast density and breast cancer tumor characteristics. *Cancer Epidemiology, Biomarkers and Prevention*. 2005 Mar;14(3):662-8. doi: 10.1158/1055-9965.EPI-04-0327. PubMed PMID: 15767347.
  11. El-Bastawissi A, **Aiello EJ**, Buist DSM, Taplin SH. Previous pregnancy outcome and breast density. *Cancer Causes and Control*. 2005 May;16(4):407-17. doi: 10.1007/s10552-004-5027-8. PubMed PMID: 15953983.
  12. **Aiello EJ**, Tworoger SS, Yasui Y, Stanczyk F, Potter J, Ulrich CM, Irwin M, McTiernan A. Associations among circulating sex hormones, insulin-like growth factor, lipids, and mammographic density in postmenopausal women. *Cancer Epidemiology, Biomarkers and Prevention*. 2005 Jun;14(6):1411-7. doi: 10.1158/1055-9965.EPI-04-0920. PubMed PMID: 15941949.
  13. Irwin M, **Aiello EJ**, McTiernan A, Baumgartner RN, Baumgartner KB, Bernstein L, Gilliland FD, Ballard-Barbash R. Pre-diagnosis physical activity and mammographic breast density in pre-and post-menopausal women. *Breast Cancer Research and Treatment*. 2006 Jan;95(2):171-8. doi: 10.1007/s10549-005-9063-1. Epub 2005 Nov 30. PubMed PMID: 16319988; PubMed Central PMCID: PMC3034407.
  14. **Aiello EJ**, Taplin S, Reid R, Hobbs M, Seger D, Kamel H, Tufano J, Ballard-Barbash R. In a

- randomized controlled trial, patients preferred electronic data collection of breast cancer risk-factor information in a mammography setting. *Journal of Clinical Epidemiology*. 2006 Jan;59(1):77-81. doi: 10.1016/j.jclinepi.2005.07.007. Epub 2005 Oct 13. PubMed PMID: 16360564.
15. \*Crest AB, **Aiello EJ**, Anderson ML, Buist DSM. Varying levels of family history of breast cancer in relation to mammographic breast density (United States). *Cancer Causes and Control*. 2006 Aug;17(6):843-50. doi: 10.1007/s10552-006-0026-6. PubMed PMID: 16783612.
  16. **Aiello EJ**, Buist DSM, White E. Do breast cancer risk factors modify the association between hormone therapy and mammographic breast density? (United States). *Cancer Causes and Control*. doi: 10.1007/s10552-006-0073-z. PubMed PMID: 17111253.
  17. Buist DSM, **Aiello EJ**, Miglioretti DL, White E. Mammographic breast density, dense area, and breast area differences by phase in the menstrual cycle. *Cancer Epidemiology Biomarkers and Prevention*. 2006 Nov;15(11):2303-6. doi: 10.1158/1055-9965.EPI-06-0475. PubMed PMID: 17119062; NIHMSID:NIHMS101005.
  18. Abrahamson PE, Tworoger SS, **Aiello EJ**, Bernstein L, Ulrich CM, Gilliland FD, Stanczyk FZ, Baumgartner R, Baumgartner K, Sorensen B, Ballard-Barbash R, McTiernan A. Associations between the CYP17, CYP1B1, COMT and SHBG polymorphisms and serum sex hormones in postmenopausal breast cancer survivors. *Breast Cancer Res Treat*. 2007 Sep;105(1):45-54. doi: 10.1007/s10549-006-9426-2. Epub 2006 Nov 1. PubMed PMID: 17077994; PubMed Central PMCID: PMC2997631.
  19. Carney PA, Yi J, Abraham LA, Miglioretti DL, **Aiello EJ**, Gerrity MS, Reisch L, Sickles EA, Berns EA, Elmore JG. Reactions to Uncertainty and the Accuracy of Diagnostic Mammography. *J Gen Intern Med*. 2007 Feb;22(2):234-41. doi: 10.1007/s11606-006-0036-9. PubMed PMID: 17356992; PubMed Central PMCID: PMC1824735.
  20. Irwin M, **Aiello EJ**, McTiernan A, Bernstein L, Gilliland FD, Baumgartner RN, Baumgartner KB, Ballard-Barbash R. Physical activity, body mass index, and mammographic density in postmenopausal breast cancer survivors. *J Clin Oncol*. 2007 Mar 20;25(9):1061-6. doi: 10.1200/JCO.2006.07.3965. Epub 2007 Jan 29. PubMed PMID: 17261853; PubMed Central PMCID: PMC3839099.
  21. **Aiello EJ**, Buist DSM, Wagner EH, Tuzzio L, Greene SM, Lamerato L, Field TS, Herrinton LJ, Haque R, Hart G, Bischoff KJ, Geiger AM. Diffusion of Aromatase Inhibitors for Breast Cancer Therapy Between 1996-2003 in the Cancer Research Network. *Breast Cancer Res Treat*. 2008 Feb;107(3):397-403. doi: 10.1007/s10549-007-9558-z. Epub 2007 Mar 28. PubMed PMID: 17393300.
  22. Miglioretti DL, Abraham L, Smith-Bindman R, Carney PA, Osterman LR, Yi JP, **Bowles EJA**, Berns EA, Brenner J, Yankaskas B, Elmore JG. Radiologist characteristics associated with interpretive performance of diagnostic mammography. *JNCI* 2007 Dec 19;99(24):1854-63. doi: 10.1093/jnci/djm238. Epub 2007 Dec 11. PubMed PMID: 18073379; PubMed Central PMCID: PMC3144707.
  23. **Bowles EJA**, Tuzzio L, Wiese C, Kirlin B, Greene SM, Wagner EH. Understanding high-quality cancer care – a summary of expert perspectives. *CANCER*. 2008 Feb 15;112(4):934-42. doi: 10.1002/cncr.23250. PubMed PMID: 18181099.
  24. Atkinson C, Newton KM, **Bowles EJA**, Yong M, Lampe JW. Demographic, anthropometric, and lifestyle factors and dietary intakes in relation to daidzein-metabolizing phenotypes among premenopausal women in the United States. *The American Journal of Clinical Nutrition*. 2008 Mar;87(3):679-87. doi: 10.1093/ajcn/87.3.679. PubMed PMID: 18326607.
  25. **Bowles EJA**, Miglioretti DL, Sickles E, Abraham L, Carney P, Yankaskas B, Elmore JG. Accuracy of short-interval follow-up mammograms by patient and radiologist characteristics. *American Journal of Roentgenology*. 2008 May;190(5):1200-8. doi: 10.2214/AJR.07.3041. PubMed PMID: 18430832; PubMed Central PMCID: PMC3148073.
  26. \*Welsh ML, Buist DSM, **Bowles EJA**, Anderson, ML, Elmore JG, Li, CI. Population-based

- estimates of the relation between breast cancer risk, tumor subtype, and family history. *Breast Cancer Research and Treatment*. 2009 Apr;114(3):549-58. doi: 10.1007/s10549-008-0026-1. Epub 2008 Apr 25. PubMed PMID: 18437558; PubMed Central PMCID: PMC2692346.
27. Atkinson C, Newton KM, **Bowles EJA**, Lehman CD, Stanczyk FZ, Westerlind KC, Li L, Lampe JW. Daidzein-metabolizing phenotypes in relation to mammographic breast density among premenopausal women in the United States. *Breast Cancer Res Treat*. 2009 Aug;116(3):587-94. doi: 10.1007/s10549-008-0199-7. Epub 2008 Sep 28. PubMed PMID: 18821061.
  28. Geller B, **Bowles EJA**, Sohng HY, Brenner JR, Miglioretti DL, Carney PA, Elmore JG. Radiologists' performance and their enjoyment of interpreting screening mammograms. *American Journal of Roentgenology*. 2009 Feb; 192(2):361-9. doi: 10.2214/AJR.08.1647. PubMed PMID: 19155395; PubMed Central PMCID: PMC2824325.
  29. Chubak J, **Bowles EJA**, Terry MB, Trentham-Dietz A, Buist DSM. Antidepressant medications and change in mammographic density in postmenopausal women. *Cancer Epidemiol Biomarkers Prev*. 2009 Feb; 18(2):676-9. doi: 10.1158/1055-9965.EPI-08-1017. Epub 2009 Feb 3. PubMed PMID: 19190163; PubMed Central PMCID: PMC2640441.
  30. Yong M, Atkinson C, Newton KM, **Bowles EJA**, Stanczyk FZ, Westerlind KC, Hold VL, Schwartz SM, Leisenring WM, Lampe JW. Associations between endogenous sex hormone levels and mammographic and bone densities in premenopausal women. *Cancer Causes Control*. 2009 Sep;20(7):1039-53. doi: 10.1007/s10552-009-9321-3. Epub 2009 Mar 12. PubMed PMID: 19280356; PubMed Central PMCID: PMC2817944.
  31. McTiernan A, Wang CY, Sorensen B, Xiao L, Buist DSM, **Bowles EJA**, White E, Rossing MA, Potter J, Urban N. No effect of aspirin on mammographic density in a randomized controlled clinical trial. *Cancer Epidemiol Biomarkers Prev*. 2009 May; 18(5):1524-30. doi: 10.1158/1055-9965.EPI-08-1088. PubMed PMID: 19423529; PubMed Central PMCID: PMC2689709.
  32. **Bowles EJA**, Geller BM. Best ways to provide feedback to radiologists on mammography performance. *American Journal of Roentgenology*. 2009 Jul;193(1):157-64. doi: 10.2214/AJR.08.2051. PubMed PMID: 19542408; PubMed Central PMCID: PMC2714544.
  33. Abraham L, Geller BM, Yankaskas BC, **Bowles EJA**, Karliner LS, Taplin SH, Miglioretti DL. Accuracy of self-reported breast cancer among women undergoing mammography. *Breast Cancer Res Treat*. 2009 Dec;118(3):583-92. doi: 10.1007/s10549-009-0375-4. Epub 2009 Mar 20. PubMed PMID: 19301119; PubMed Central PMCID: PMC2784159.
  34. **Bowles EJA**, Tuzzio L, Ritzwoller DP, Ross T, Wagner EH, Neslund-Dudas C, Altschuler A, Quinn V, Hornbrook M, Nekhlyudov L. Accuracy and complexities of using automated clinical data for capturing chemotherapy administrations: implications for future research. *Medical Care*. 2009 Oct;47(10):1091-7. doi: 10.1097/MLR.0b013e3181a7e569. PubMed PMID: 19648826; PubMed Central PMCID: PMC2764807.
  35. Buist DSM, Anderson ML, Reed SD, **Bowles EJA**, Fitzgibbons ED, Gandara JC, Seger D, Newton KM. Short-term hormone therapy suspension and mammography recall: a randomized trial. *Annals of Internal Medicine*. 2009 Jun 2; 150(11): 752-65. doi: 10.7326/0003-4819-150-11-200906020-00003. PubMed PMID: 19487710; PubMed Central PMCID: PMC2803099.
  36. Reed SD, Buist DSM, Anderson ML, **Bowles EJA**, Fitzgibbons D, Seger D, Newton KM. Short-term (1-2 months) Hormone Therapy Cessation Before Mammography. *Menopause*. 2009 Nov-Dec;16(6):1125-31. doi: 10.1097/gme.0b013e3181a5ce60. PubMed PMID: 19455069; PubMed Central PMCID: PMC2783807.
  37. Carney PA, Kettler M, Cook AJ, Geller BM, Karliner L, Miglioretti DL, **Bowles EJA**, Buist DS, Gallagher TH, Elmore JG. An Assessment of the Likelihood, Frequency, and Content of Verbal Communication Between Radiologists and Women Receiving Screening and Diagnostic Mammography. *Academic Radiology*. 2009 Sep;16(9):1056-63. doi: 10.1016/j.acra.2009.02.023. Epub 2009 May 12. PubMed PMID: 19442539; PubMed Central PMCID: PMC2746626.
  38. Cook AJ, Elmore JG, Miglioretti DL, Sickles EA, **Bowles EJA**, Cutter GR, Carney PA. Decreased

- accuracy in interpretation of community-based screening mammography for women with multiple clinical risk factors. *Journal of Clinical Epidemiology* 2010 Apr;63(4):441-51. doi: 10.1016/j.jclinepi.2009.06.008. Epub 2009 Sep 9. PubMed PMID: 19744825; PubMed Central PMCID: PMC2837135.
39. **Bowles EJA**, Sickles EA, Miglioretti DL, Carney PA, Elmore JG. Recommendation for short-interval follow-up examinations after a probably benign assessment: is clinical practice consistent with BI-RADS guidance? *AJR Am J Roentgenol.* 2010 Apr;194(4):1152-9. doi: 10.2214/AJR.09.3064. PubMed PMID: 20308525; PubMed Central PMCID: PMC2861652.
  40. Yong M, Schwartz SM, Atkinson C, Makar KW, Thomas SS, Newton KM, **Bowles EJA**, Holt VL, Leisenring WM, Lampe JW. Associations between polymorphisms in glucuronidation and sulfation enzymes and mammographic breast density in premenopausal women in the United States. *Cancer Epidemiol Biomarkers Prev.* 2010 Feb;19(2):537-46. doi: 10.1158/1055-9965.EPI-09-0898. PubMed PMID: 20142249; PubMed Central PMCID: PMC2820123.
  41. **Bowles EJA**, Anderson ML, Reed SD, Newton KM, Fitzgibbons ED, Seger D, Buist DS. Mammographic breast density and tolerance for short-term postmenopausal hormone therapy suspension. *J Womens Health (Larchmt).* 2010 Aug;19(8):1467-74. doi: 10.1089/jwh.2009.1681. PubMed PMID: 20575711; PubMed Central PMCID: PMC2941404.
  42. Elmore JG, **Bowles EJA**, Geller B, Oster NV, Carney PA, Miglioretti DL, Buist DM, Kerlikowske K, Sickles EA, Onega T, Rosenberg RD, Yankaskas BC. Radiologists' Attitudes and Use of Mammography Audit Reports. *Academic Radiology* 2010 Jun;17(6):752-60. doi: 10.1016/j.acra.2010.02.010. PubMed PMID: 20457418; PubMed Central PMCID: PMC2894027.
  43. Phipps AI, Ichikawa L, **Bowles EJA**, Carney PA, Geller BM, Kerlikowske K, Miglioretti DL, Buist DS, for the Breast Cancer Surveillance Consortium. Defining menopausal status in epidemiologic studies: an applied comparison of multiple approaches and their effects on breast cancer rates. *Maturitas.* 2010 Sep;67(1):60-6.
  44. De Roos AJ, Deeg HJ, Onstad L, Kopecky KJ, **Bowles EJA**, Yong M, Fryzeck J, Davis S. Incidence of Myelodysplastic Syndromes (MDS) within a Non-Profit Health Care System in Western Washington State, 2005-2006. *American Journal of Hematology* 2010 Oct;85(10):765-70. doi: 10.1002/ajh.21828. PubMed PMID: 20815079.
  45. Onega T, **Bowles EJA**, Miglioretti DL, Carney PA, Geller BM, Yankaskas BC, Kerlikowske K, Sickles EA, Elmore JG. Radiologists' perceptions of computer aided detection versus double reading for mammography interpretation. *Academic Radiology* 2010;17(10):1217-26. doi: 10.1016/j.acra.2010.05.007. PubMed PMID: 20832024; PubMed Central PMCID: PMC3149895.
  46. Wagner WH, **Bowles EJA**, Greene SM, Tuzzio L, Wiese CJ, Kirlin B, Clauser SB. The quality of cancer patient experience: perspectives of patients, family members, providers, and experts. *Quality and Safety in Health Care* 2010 Dec;19(6):484-9. doi: 10.1136/qshc.2010.042374. PubMed PMID: 21127109.
  47. Carney PA, Geller BM, Sickles EA, Miglioretti DL, **Bowles EJA**, Abraham L, Feig SA, Brown D, Cook AJ, Yankaskas BC, Elmore JG. Feasibility and satisfaction with a tailored web-based audit intervention for recalibrating radiologists' thresholds for conducting additional work-up. *Acad Radiol.* 2011 Mar;18(3):369-76. doi: 10.1016/j.acra.2010.10.011. Epub 2010 Dec 30. PubMed PMID: 21193335; PubMed Central PMCID: PMC3034778.
  48. Wernli KJ, **Bowles EJA**, Haneuse S, Elmore JG, Buist DSM. Timing of follow-up after abnormal screening and diagnostic mammograms. *Am J Managed Care.* 2010 Feb; 17(2):162-7. PubMed PMID: 21473665; PubMed Central PMCID: PMC3151253.
  49. Sprague BL, Trentham-Dietz A, Gangnon RE, Buist DSM, Burnside ES, **Bowles EJA**, Stanczyk FZ, Sisney GS. Circulating sex hormones and mammographic breast density among postmenopausal women. *Hormones and Cancer* 2011 Feb 1; 2(1):62-72. doi: 10.1007/s12672-010-0056-0. PubMed PMID: 21318123; PubMed Central PMCID: PMC3035325.
  50. Loo LWM, Wang Y, Flynn EM, Lund MJ, **Bowles EJA**, Buist DSM, Liff JM, Flagg EW, Coates RJ, Eley JW, Hsu L, Porter PL. Genome-wide copy number alterations in subtypes of invasive breast

- cancers in young white and African-American women. *Breast Cancer Res Treatment*. 2011 May; 127(1):297-308. doi: 10.1007/s10549-010-1297-x. Epub 2011 Jan 25. PubMed PMID: 21264507; PubMed Central PMCID: PMC3224104.
51. Adams SV, Newcomb PA, Shafer MM, Atkinson C, **Bowles EJA**, Newton KM, Lampe JW. Sources of Cadmium Exposure Among Healthy Premenopausal Women. *Science of the Total Environment*. 2011 Apr 1; 409(9):1632-7. doi: 10.1016/j.scitotenv.2011.01.037. Epub 2011 Feb 17. PubMed PMID: 21333327; PubMed Central PMCID: PMC3056571.
  52. Carney PA, **Bowles EJA**, Sickles EA, Geller BM, Feig SA, Jackson S, Brown D, Cook A, Yankaskas BC, Miglioretti DL, Elmore JG. Using a tailored web-based intervention to set goals to reduce unnecessary recall. *Acad Radiol*. 2011 Apr; 18(4):495-503. doi: 10.1016/j.acra.2010.11.017. Epub 2011 Jan 20. PubMed PMID: 21251856; PubMed Central PMCID: PMC3065970.
  53. Adams SV, Newcomb PA, Shafer MM, Atkinson C, **Bowles EJA**, Newton KM, Lampe JW. Urinary Cadmium and Mammographic Density in Premenopausal Women. *Breast Cancer Res Treatment*. 2011 Aug; 128(3):837-44. doi: 10.1007/s10549-011-1383-8. Epub 2011 Feb 15. PubMed PMID: 21327468; PubMed Central PMCID: PMC3115389.
  54. Carney PA, Cook AJ, Miglioretti DL, Feig SA, **Bowles EJA**, Geller BM, Kerlikowske K, Kettler M, Onega T, Elmore JG. Use of clinical history affects accuracy of interpretive performance of screening mammography. *Journal of Clinical Epidemiology*. 2012 Feb; 65(2):219-30. doi: 10.1016/j.jclinepi.2011.06.010. Epub 2011 Oct 15. PubMed PMID: 22000816; PubMed Central PMCID: PMC3253253.
  55. Clauser SB, Wagner EH, **Bowles EJA**, Tuzzio L, Greene SM. Improving modern cancer care through information technology. *Am J Prev Med* 2011;40(5S2):S198 –S207. doi: 10.1016/j.amepre.2011.01.014. Review. PubMed PMID: 21521595; PubMed Central PMCID: PMC3119205.
  56. Tom SE, Anderson ML, Landis CA, **Bowles EJA**, Woods NF, Reed SD, Newton KM, Buist DS. Sleep problems after short-term hormone therapy suspension: secondary analysis of a randomized trial. *Menopause*. 2011 Nov;18(11):1184-90. doi: 10.1097/gme.0b013e31821d6d33. PubMed PMID: 21785373; PubMed Central PMCID: PMC3203993.
  57. Newton KM, Anderson ML, Reed SD, **Bowles EJA**, Buist DS. Factors associated with non-compliance with hormone therapy cessation before screening mammography. *Climacteric*. 2011 Apr;14(2):268-74. doi: 10.3109/13697137.2010.520172. Epub 2010 Oct 27. PubMed PMID: 20979462.
  58. \*Lowry S, **Bowles EJA**, Anderson M, Buist DSM. Predictors of breast density change after hormone therapy cessation: results from a randomized trial. *Cancer Epidemiology Biomarkers and Prevention*, 2011 Oct; 20(10):2309-12.
  59. Sprague BL, Trentham-Dietz A, Gangnon RE, Buist DS, Burnside ES, **Bowles EJA**, Stanczyk FZ, Sisney GS, Skinner HG. The Vitamin D pathway and mammographic breast density among postmenopausal women. *Breast Cancer Res Treat*. 2012 Jan; 131(1):255-65. doi: 10.1007/s10549-011-1726-5. Epub 2011 Aug 17. PubMed PMID: 21847642; PubMed Central PMCID: PMC3250989.
  60. **Bowles EJA**, Buist DSM, Chubak J, Yu O, Johnson J, Chestnut J, Boudreau DM. Endocrine therapy initiation from 2001 through 2008 varies by age of breast cancer diagnosis and tumor size. *Journal of Oncology Practice*. 2012 Mar;8(2):113-20. doi: 10.1200/JOP.2011.000417. Epub 2012 Feb 21. PubMed PMID: 23077439; PubMed Central PMCID: PMC3457815.
  61. Buist DSM, Walker R, **Bowles EJA**, Carney PA, Taplin SH, Onega T, Kerlikowske K, Clinton W, Miglioretti DL. Screening mammography use among current, former, and never hormone therapy users may not explain recent declines in breast cancer incidence. *Cancer Epidemiology Biomarkers and Prevention*, 2012 May; 21(5):720-7. doi: 10.1158/1055-9965.EPI-11-1115. Epub 2012 Feb 1. PubMed PMID: 22301831; PubMed Central PMCID: PMC3348383.
  62. Delate T, **Bowles EJA**, Pardee R, Wellman RD, Habel LA, Yood MU, Nekhlyudov L, Goddard KA,

- Davis RL, McCarty CA, Onitilo AA, Feigelson HS, Fremel J, Wagner E. Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure. *Cancer Epidemiology Biomarkers and Prevention*, 2012 Apr; 21(4):673-80. doi: 10.1158/1055-9965.EPI-11-1075. Epub 2012 Feb 15. PubMed PMID: 22337532; PubMed Central PMCID: PMC3319397.
63. Ritzwoller DP, Carroll N, Delate T, O'Keefe-Rossetti M, Fishman PA, Loggers ET, **Bowles EJA**, Elston-Lefata J, Hornbrook MC. Validation of Electronic Data on Chemotherapy and Hormone Therapy Use in HMOs. *Medical Care*. 2012 Apr 23. doi: 10.1097/MLR.0b013e31824def85. PubMed PMID: 22531648; PubMed Central PMCID: PMC3406224.
  64. McCahill LE, Single RM, **Bowles EJA**, Feigelson HS, James TA, Barney T, Engel JM, Onitilo AA. Variability in reexcision following breast conservation surgery. *JAMA*. 2012 Feb 1;307(5):467-75. doi: 10.1001/jama.2012.43. PubMed PMID: 22298678.
  65. Reding KW, Atkinson C, Westerlind KC, Stanczyk F, **Bowles EJA**, Yong M, Newton KM, Lampe JW. Fruit intake associated with urinary estrogen metabolites in healthy premenopausal women. *Open Journal of Preventive Medicine*, 2012 Feb 23; 2(1). doi: 10.4236/ojpm.2012.21001. PubMed PMID: 24307982; PubMed Central PMCID: PMC3845414.
  66. Delate T, Witt DM, Ritzwoller D, Weeks JC, Kushi L, Hornbrook MC, **Bowles EJA**, Schrag D. Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer. *Oncologist*. 2012;17(3):419-27. doi: 10.1634/theoncologist.2011-0323. Epub 2012 Feb 14. PubMed PMID: 22334451; PubMed Central PMCID: PMC3316928.
  67. **Bowles EJA**, Feigelson HS, Barney T, Broecker K, Sterrett A, Bischoff K, Engel J, Gundersen G, Sheehy-Jones J, Single R, Onitilo A, James TA, McCahill LE. Improving Quality of Breast Cancer Surgery Through Development of a National Breast Cancer Surgical Outcomes (BRCASO) Research Database. *BMC Cancer*, 2012 Apr 3; 12(1):136. doi: 10.1186/1471-2407-12-136. PubMed PMID: 22472011; PubMed Central PMCID: PMC3350402.
  68. \*Lowry SJ, Loggers ET, **Bowles EJA**, Wagner EH. Evidence gaps in advanced cancer care: community-based clinicians' perspectives and priorities for CER. *Am J Manag Care*. 2012 May;18(5 Spec No. 2):SP77-83. PubMed PMID: 22693985; PubMed Central PMCID: PMC6205164.
  69. **Bowles EJA**, Boudreau DM, Chubak J, Yu O, Fujii M, Chestnut J, Buist DSM. Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. *Journal of Oncology Practice*, Nov 1, 2012: e149-e157. doi: 10.1200/JOP.2012.000543. Epub 2012 Jul 17. PubMed PMID: 23598850; PubMed Central PMCID: PMC3500489.
  70. **Bowles EJA**, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, Allen LA, Nekhlyudov L, Goddard KAB, Davis RL, Habel LA, Yood MU, McCarty C, Magid DJ, Wagner EH. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. *JNCI*, 2012 Sep 5; 104(17):1293-305. doi: 10.1093/jnci/djs317. PubMed PMID: 22949432; PubMed Central PMCID: PMC3433392.
  71. Allen LA, Yood MU, Wagner EH, **Bowles EJA**, Pardee R, Wellman R, Habel L, Nekhlyudov L, Davis RL, Onitilo AA, Magid DJ, for the Pharmacovigilance Research Group. Performance of claims-based algorithms for identifying heart failure and cardiomyopathy among patients diagnosed with breast cancer. *Medical Care*. 2014 May;52(5):e30-8. doi: 10.1097/MLR.0b013e31825a8c22. PubMed PMID: 22643199; PubMed Central PMCID: PMC3482414.
  72. Romaine MA, **Bowles EJA**, Anderson ML, Buist DS. Comparative effectiveness of mailed reminder letters on mammography screening compliance. *Prev Med*, 2012 Aug;55(2):127-30. doi: 10.1016/j.ypmed.2012.05.009. Epub 2012 May 22. PubMed PMID: 22627089; PubMed Central PMCID: PMC3694128.

73. \*Lowry SJ, Loggers ET, **Bowles EJA**, Wagner EH. Evidence gaps in advanced cancer care: community-based clinicians' perspectives and priorities for CER. *J Oncol Pract*. 2012 May;8(3 Supple):28s-33s. doi: 10.1200/JOP.2012.000569 PubMed PMID: 22942821; PubMed Central PMCID: PMC3348591.
74. Ritzwoller DP, Carroll N, Delate T, Hornbrook MC, Kushi L, **Bowles EJA**, Freml JM, Huang K, Loggers ET. Patterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the Cancer Research Network. *Lung Cancer*, 2012 Dec;78(3):245-52. doi: 10.1016/j.lungcan.2012.09.008. Epub 2012 Sep 27. PubMed PMID: 23022316; PubMed Central PMCID: PMC3490021.
75. \*Lowry SJ, Sprague BL, **Bowles EJA**, Hedman CJ, Hemming J, Hampton JM, Burnside ES, Sisney GA, Buist DS, Trentham-Dietz A. Mammographic breast density and serum phytoestrogen levels. *Nutr Cancer* 2012 Aug; 64(6):783-9. doi: 10.1080/01635581.2012.707279. Epub 2012 Aug 3. PubMed PMID: 22860715; PubMed Central PMCID: PMC4055295.
76. Goddard KA, **Bowles EJA**, Spencer Feigelson H, Habel LA, Alford SH, McCarty CA, Nekhlyudov L, Onitilo AA, Rahm AK, Webster JA. Utilization of HER2 genetic testing in a multi-institutional observational study. *Am J Manag Care*. 2012 Nov;18(11):704-12. PubMed PMID: 23198713; PubMed Central PMCID: PMC4061608.
77. Horner K, Ludman E, McCorkle R, Canfield E, Flaherty L, Min J, Miyoshi J, Lapham B, **Bowles EJA**, Wagner E. An oncology nurse navigator program designed to eliminate gaps in early cancer care. *Clin J Oncol Nurs*. 2013 Feb;17(1):43-8. doi: 10.1188/13.CJON.43-48. PubMed PMID: 23372095.
78. Feigelson HS, James TA, Single RM, Onitilo AA, **Bowles EJA**, Barney T, Bakerman JE, McCahill LE. Factors associated with the frequency of initial total mastectomy: Results of a multi-institutional study. *J Am Coll Surg*, 2013 May; 216(5):966-75. doi: 10.1016/j.jamcollsurg.2013.01.011. Epub 2013 Mar 13. PubMed PMID: 23490543; PubMed Central PMCID: PMC3678356.
79. Sprague BL, Trentham-Dietz A, Hedman CJ, Wang J, Hemming JDC, Hampton JM, Buist DSM, **Bowles EJA**, Sisney GS, Burnside ES. Circulating serum xenoestrogens and mammographic breast density. *Breast Cancer Research*. 2013 May 27;15(3):R45. doi: 10.1186/bcr3432. PubMed PMID: 23710608; PubMed Central PMCID: PMC4053153.
80. Onitilo AA, Onesti JK, Single RM, Engel JM, James TA, **Bowles EJA**, Feigelson HS, Barney T, McCahill LE. Utilization of neoadjuvant chemotherapy varies in the treatment of women with invasive breast cancer. *PLoS One*, 2013 Dec 20;8(12):e84535. doi: 10.1371/journal.pone.0084535. eCollection 2013. PubMed PMID: 24376822; PubMed Central PMCID: PMC3869842.
81. Wagner EH, Ludman EJ, **Bowles EJA**, Penfold R, Reid RJ, Rutter CM, Chubak J, McCorkle R. Nurse navigators in early cancer care: A randomized controlled trial. *J Clin Oncol*. 2014 Jan 1;32(1):12-8. doi: 10.1200/JCO.2013.51.7359. Epub 2013 Nov 25. PubMed PMID: 24276777; PubMed Central PMCID: PMC3867643.
82. Chubak J, **Bowles EJA**, Tuzzio L, Ludman E, Rutter CM, Reid RJ, Wagner E. Perspectives of cancer survivors on the role of different healthcare providers in an integrated delivery system. *Journal of Cancer Survivorship: Research and Practice*. 2014 Jun;8(2):229-38. doi: 10.1007/s11764-013-0335-1. Epub 2013 Dec 19. PubMed PMID: 24352871; PubMed Central PMCID: PMC4016186.
83. Wirtz HS, Boudreau DM, Gralow JR, Barlow WE, Gray SL, **Bowles EJA**, Buist DSM. Factors associated with long-term adherence to surveillance mammography recommendations among breast cancer survivors. *Breast Cancer Res Treat*. 2014 Feb; 143(3):541-50. doi: 10.1007/s10549-013-2816-3. Epub 2014 Jan 10. PubMed PMID: 24407530; PubMed Central PMCID: PMC3935518.
84. Delate T, Won K, Carroll NM, Kushi L, Hornbrook M, **A Bowles EJA**, Menter A, Loggers ET, Ritzwoller D. Factors Associated with First-line Bevacizumab Use in Advanced, Non-Squamous,

- Non-Small Cell Lung Cancer. *J Cancer Research and Therapy*, 2014; 2(1):1-8. doi: 10.14312/2052-4994.2014-1.
85. Ritzwoller D, Carroll NM, Delate T, Hornbrook M, Kushi L, **Bowles EJA**, Loggers ET, Menter A. Comparative effectiveness of adjunctive bevacizumab for advanced lung cancer: the Cancer Research Network Experience. *Journal of Thoracic Oncology* 2014 May;9(5):692-701. doi: 10.1097/JTO.000000000000127. PubMed PMID: 24633407; PubMed Central PMCID: PMC5083067.
  86. **Bowles EJA**, Wernli KJ, Gray HJ, Bogart A, Delate T, O'Keefe-Rosetti M, Nekhlyudov L, Loggers ET. Diffusion of Intraperitoneal Chemotherapy in Women with Advanced Ovarian Cancer in Community Settings 2003-2008: The Effect of the NCI Clinical Recommendation. *Front Oncol*. 2014;4:43. doi: 10.3389/fonc.2014.00043. eCollection 2014. PubMed PMID: 24653978; PubMed Central PMCID: PMC3948091.
  87. Boudreau D, Yu O, Chubak J, Wirtz HS, **Bowles EJA**, Fujii M, Buist DS. Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. *Breast Cancer Res Treat*. 2014 Apr; 144(2):405-16. doi: 10.1007/s10549-014-2870-5. Epub 2014 Feb 21. PubMed PMID: 24557337; PubMed Central PMCID: PMC3988288.
  88. Jones SM, Ludman EJ, McCorkle R, Reid R, **Bowles EJA**, Penfold R, Wagner EH. A differential item function analysis of somatic symptoms of depression in people with cancer. *J Affect Disord*. 2015 Jan 1; 170:131-7. doi: 10.1016/j.jad.2014.09.002. Epub 2014 Sep 10. PubMed PMID: 25240839; PubMed Central PMCID: PMC4253856.
  89. Nyante SJ, Sherman ME, Pfeiffer RM, Berrington de Gonzalez A, Brinton LA, **Bowles EJA**, Hoover RN, Glass A, Gierach GL. Prognostic significance of mammographic density change after initiation of tamoxifen therapy for ER-positive breast cancer. *J Natl Cancer Inst*. 2015 Feb 6; 107(3). doi: 10.1093/jnci/dju425. Print 2015 Mar. PubMed PMID: 25663687; PubMed Central PMCID: PMC4334825.
  90. Gard CC, **Bowles EJA**, Miglioretti DL, Taplin SH, Rutter CM. Misclassification of breast imaging reporting and data system (BI-RADS) mammographic density and implications for breast density reporting legislation. *The Breast Journal*. 2015 Sep-Oct; 21 (5):481-9. doi: 10.1111/tbj.12443. Epub 2015 Jul 1. PubMed PMID: 26133090; PubMed Central PMCID: PMC4558212.
  91. \*Gao H, **Bowles EJA**, Carrell DS, Buist DS. Using natural language processing to extract mammographic findings. *J Biomedical Informatics*. 2015 Apr; 54:77-84. doi: 10.1016/j.jbi.2015.01.010. Epub 2015 Feb 3. PubMed PMID: 25661260; PubMed Central PMCID: PMC4408241.
  92. \*Wieneke AE, **Bowles EJA**, Cronkite D, Wernli KJ, Gao H, Carrell D, Buist DSM. Validation of natural language processing to extract breast cancer pathology procedures and results. *J Pathol Inform*. 2015 June 23;6:38. doi: 10.4103/2153-3539.159215. eCollection 2015. PubMed PMID: 26167382; PubMed Central PMCID: PMC4485196.
  93. Carroll NM, Delate T, Menter A, Hornbrook MC, Kushi L, **Bowles EJA**, Loggers ET, Ritzwoller DP. Use of bevacizumab in community settings: Toxicity profile and risk of hospitalization in patients with advanced non-small-cell lung cancer. *J Oncol Pract*. 2015 Sep; 11(5):356-62. doi: 10.1200/JOP.2014.002980. Epub 2015 Jun 9. PubMed PMID: 26060223; PubMed Central PMCID: PMC4575400.
  94. Ludman EJ, McCorkle R, **Bowles EA**, Rutter CM, Chubak J, Tuzzio L, Jones S, Reid RJ, Penfold R, Wagner EH. Do depressed newly diagnosed cancer patients differentially benefit from nurse navigation? *Gen Hosp Psychiatry*. 2015 May-Jun; 37(3):236-9. doi: 10.1016/j.genhosppsych.2015.02.008. Epub 2015 Feb 28. PubMed PMID: 25835508; PubMed Central PMCID: PMC4442728.
  95. **Bowles EJA**, Larson EB, Pong RP, Walker RL, Anderson ML, Yu O, Gray SL, Crane PK, Dublin S. Anesthesia exposure and risk of dementia and Alzheimer's disease: a prospective study. *J Am*

- Geriatr Soc.* 2016 Mar; 64(3):602-7. doi: 10.1111/jgs.14024. Epub 2016 Feb 11. PubMed PMID: 26865152; PubMed Central PMCID: PMC4803643.
96. Nyante SJ, Sherman ME, Pfeiffer RM, Berrington de Gonzalez A, Brinton LA, **Bowles EJA**, Hoover RN, Glass A, Gierach GL. Longitudinal change in mammographic density among ER-positive breast cancer patients using tamoxifen. *CEBP* 2016 Jan;25(1):212-6.
  97. Chubak J, **Bowles EJA**, Yu O, Buist DS, Fujii M, Boudreau DM. Breast cancer recurrence in relation to antidepressant use. *Cancer Causes Control.* 2016 Jan;27(1):125-36. doi: 10.1007/s10552-015-0689-y. Epub 2015 Oct 30. PubMed PMID: 26518198; PubMed Central PMCID: PMC4913547.
  98. Nichols HB, **Bowles EJA**, Islam J, Madziwa L, Sturmer T, Tran D-T, Buist DSM. Tamoxifen initiation after ductal carcinoma in situ. *Oncologist.* 2016 Feb; 21(2):134-40. doi: 10.1634/theoncologist.2015-0310. Epub 2016 Jan 14. PubMed PMID: 26768485; PubMed Central PMCID: PMC4746086.
  99. Mullooly M, Pfeiffer RM, Nyante SJ, Heckman-Stoddard BM, Perloff M, Jatoi I, Brinton LA, **Bowles EJA**, Hoover RN, Glass A, Berrington de Gonzalez A, Sherman ME, Gierach GL. Mammographic density as a biosensor of tamoxifen effectiveness in adjuvant endocrine treatment of breast cancer: opportunities and implications. *JCO.* 2016 Mar 28. 2016 Jun 20;34(18):2093-7. doi: 10.1200/JCO.2015.64.4492. Epub 2016 Mar 28. PubMed PMID: 27022110; PubMed Central PMCID: PMC4962703.
  100. **Bowles EJ**, Gao H, Brandzel S, Bradford SC, Buist DS. Comparative effectiveness of two outreach strategies for cervical cancer screening. *Prev Med.* 2016 May; 86:19-27. doi: 10.1016/j.ypmed.2016.01.016. Epub 2016 Jan 25. PubMed PMID: 26820221; PubMed Central PMCID: PMC4902104.
  101. Brandzel S, Chang E, Tuzzio L, Campbell C, Coronado N, **Bowles EJA**, Bradford SC, Buist DS. Latina and Black/African American women's perspectives on cancer screening and cancer screening reminders. *J Racial Ethn Health Disparities.* 2016 Nov 18;. doi: 10.1007/s40615-016-0304-2. [Epub ahead of print] PubMed PMID: 27864808; PubMed Central PMCID: PMC5436953.
  102. Buist DSM, Gao H, Anderson ML, Onega T, Brandzel S, Rabelhofer RA, Bradford SC, **Bowles EJA**. Breast cancer screening outreach effectiveness: mammogram-specific reminders vs comprehensive preventive services birthday letters. *Prev Med.* 2017 Sep;102:49-58. doi: 10.1016/j.ypmed.2017.06.028. Epub 2017 Jun 24. PubMed PMID: 28655547; PubMed Central PMCID: PMC5638650.
  103. Lin JS, **Bowles EJA**, Williams SB, Morrison CC. Screening for thyroid cancer: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA* 2017 May 9;317(18):1888-1903. doi: 10.1001/jama.2017.0562. Review. PubMed PMID: 28492904.
  104. **Bowles EJA**, Walker RL, Anderson ML, Dublin S, Crane PK, Larson EB. Risk of Alzheimer's disease following a cancer diagnosis. *PLOS ONE.* 2017 Jun 20;12(6):e0179857. doi: 10.1371/journal.pone.0179857. eCollection 2017. PubMed PMID: 28632787; PubMed Central PMCID: PMC5478144.
  105. Gray SL, Walker R, Dublin S, Yu O, **Bowles EJA**, Anderson ML, Crane PK, Larson EB. Proton pump inhibitor use and dementia risk. *J Am Geriatr Soc* 2018 Feb; 66(2):247-253. doi: 10.1111/jgs.15073. Epub 2017 Nov 14. PubMed PMID: 29134629; PubMed Central PMCID: PMC5809315.
  106. Brandzel SD, **Bowles EJA**, Wieneke A, Bradford SC, Kimbel K, Goa H, Buist DSM. Cancer screening reminders: addressing the spectrum of patient preferences. *Perm J.* 2017; 21:17-051. doi: 10.7812/TPP/17-051. PubMed PMID: 29035189; PubMed Central PMCID: PMC5638633.
  107. Brentnall AR, Cuzick J, Buist DSM, **Bowles EJA**. Long-term accuracy of breast cancer risk assessment combining classical factors and breast density: a cohort study. *JAMA Oncology*

- 2018 Sep; 4(9):e180174. doi: 10.1001/jamaoncol.2018.0174. Epub 2018 Sep 13. PubMed PMID: 29621362; PubMed Central PMCID: PMC6143016.
108. Chubak J, Yu O, Ziebell RA, **Bowles EJA**, Sterrett AT, Fujii MM, Boggs JM, Burnett-Hartman AN, Boudreau DM, Chen L, Floyd JS, Ritzwoller DP, Hubbard RA. Risk of colon cancer recurrence in relation to diabetes. *Cancer Causes Control*. 2018 Nov;29(11):1093-1103. doi: 10.1007/s10552-018-1083-3. Epub 2018 Sep 22. PubMed PMID: 30244297; PubMed Central PMCID: PMC6230488.
109. Sprague BL, Kerlikowske K, Bowles EJA, Rauscher GH, Lee CI, Tosteson ANA, Miglioretti DL. Trends in Clinical Breast Density Assessment From the Breast Cancer Surveillance Consortium. *J Natl Cancer Inst*. 2019 Jun 1;111(6):629-632. doi: 10.1093/jnci/djz210. PubMed PMID: 30624682; PubMed Central PMCID: PMC6579740.
110. Knerr S, **Bowles EJA**, Leppig KA, Buist DSM, Gao H, Wernli KJ. Trends in BRCA test utilization in an integrated health system, 2005-2015. *Journal of the National Cancer Institute* 2019 Feb 8, 111(8):795-802. doi: 10.1093/jnci/djz008. PubMed PMID: 30753636; PubMed Central PMCID: PMC6695306.
111. Brooks GA, Uno H, **Bowles EJA**, Menter AR, O’Keeffe Rosetti M, Tosteson ANA, Ritzwoller DP, Schrag D. Hospitalization risk during chemotherapy for advanced cancer: Development and validation of risk-stratification models using real-world data. *JCO Clinical Cancer Informatics* 2019 Apr; 3:1-10. doi: 10.1200/CCI.18.00147. PubMed PMID: 30995122; PubMed Central PMCID: PMC6784532.
112. Boudreau DM, Chen L, Yu O, **Bowles EJA**, Chubak J. Risk of second breast cancer events with chronic opioid use in breast cancer survivors. *Pharmacoepidemiology and Drug Safety* 2019 May;28(5): 740-753. doi: 10.1002/pds.4779. Epub 2019 Apr 3. PubMed PMID: 30945381; PubMed Central PMCID: PMC6553619.
113. Pocobelli G, Yu O, Ziebell RA, **Bowles EJA**, Fujii MM, Sterrett AT, Boggs JM, Chen L, Boudreau DM, Ritzwoller DP, Hubbard RA, Chubak J. Use of antidepressants after colon cancer diagnosis and risk of recurrence. *Psychooncology*. 2019 Apr;28(4):750-758. doi: 10.1002/pon.5015. Epub 2019 Feb 14. PubMed PMID: 30703275; PubMed Central PMCID: PMC6445707.
114. **Bowles EJA**, Crane PK, Walker RL, Chubak J, LaCroix AZ, Anderson ML, Rosenberg D, Keene CD, Larson EB. Cognitive resilience to Alzheimer’s disease pathology in the human brain. *Journal of Alzheimer’s Disease* 2019;68(3):1071-1083. doi: 10.3233/JAD-180942. PubMed PMID: 30909217; PubMed Central PMCID: PMC8357030.
115. **Bowles EJA**, Yu O, Ziebell R, Chen L, Boudreau DM, Ritzwoller DP, Hubbard RA, Boggs JM, Burnett-Hartman AN, Sterrett A, Fujii M, Chubak J. Cardiovascular medication use and risks of colon cancer recurrences and additional cancer events: a cohort study. *BMC Cancer*. 2019 Mar 27;19(1):270. doi: 10.1186/s12885-019-5493-8. PubMed PMID: 30917783; PubMed Central PMCID: PMC6437861.
116. Sun L, Brentnall A, Patel S, Buist DSM, **Bowles EJA**, Evans DGR, Eccles D, Hopper J, Li S, Southey M, Duffy S, Cuzick J, Dos Santos Silva I, Miners A, Sadique Z, Yang L, Legood R, Manchanda R. A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer. *JAMA Oncol*. 2019 Oct 3;. doi: 10.1001/jamaoncol.2019.3323. [Epub ahead of print] PubMed PMID: 31580391; PubMed Central PMCID: PMC6777250.
117. Smith-Bindman R, Kwan ML, Marlow EC, Theis MK, Bolch W, Cheng SY, **Bowles EJA**, Duncan JR, Greenlee RT, Kushi LH, Pole JD, Rahm AK, Stout NK, Weinmann S, Miglioretti DL. Trends in use of medical imaging in US health care systems and in Ontario, Canada, 2000-2016. *JAMA*. 2019 Sep 3;322(9):843-856.
118. Kwan ML, Miglioretti DL, Marlow EC, **Bowles EJA**, Weinmann S, Cheng SY, Deosaransingh KA, Chavan P, Moy LM, Bolch WE, Duncan JR, Greenlee RT, Kushi LH, Pole JD, Rahm AK, Stout NK, Smith-Bindman R. Trends in Medical Imaging During Pregnancy in the United States and Ontario, Canada, 1996 to 2016. *JAMA Netw Open*. 2019 Jul 3;2(7):e197249. doi:

- 10.1001/jamanetworkopen.2019.7249. PubMed PMID: 31339541; PubMed Central PMCID: PMC6659354.
119. Henrikson NB, **Bowles EJA**, Blasi PR, Morrison CC, Nguyen M, Pillarisetty VG, Lin JS. Screening for pancreatic cancer: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA*. 2019 Aug 6;322(5):445-454. doi: 10.1001/jama.2019.6190. PubMed PMID: 31386140.
  120. Chen L, Chubak J, Pocobelli G, Ziebell RA, **Bowles EJA**, Fujii MM, Sterrett AT, Boggs JM, Burnett-Hartman AN, Ritzwoller DP, Hubbard RA, Boudreau DM. Changes in use of opioid therapy after colon cancer diagnosis: a population-based study. *Cancer Causes & Control* 2019 October 30; 30(12):1341-1350. PubMed PMID: 31667710; PubMed Central PMCID: PMC6863090.
  121. Mullooly M, Nyante SJ, Pfeiffer RM, Cora R, Butcher D, Sternberg L, **Bowles EJA**, Fan S, Figueroa JD, Weinmann S, Hoover RN, Brinton LA, Berrington de Gonzalez A, Glass A, Sherman ME, Gierach GL. Involution of breast lobules, mammographic breast density and prognosis among tamoxifen-treated estrogen receptor-positive breast cancer patients. *Journal of Clinical Medicine*. 2019 Nov 4;9(11). doi: 10.3390/jcm8111868. PubMed PMID: 31689948; PubMed Central PMCID: PMC6912285.
  122. Gray SL, Marcum ZA, Dublin S, Walker RL, Golchin N, Rosenberg D, **Bowles EJA**, Crane PK, Larson EB. Association between medications acting on the central nervous system and fall-related injuries in community dwelling older adults: a new user cohort study. *J Gerontol Med Sci*. 2020 Apr 17;75(5):1003-1009. doi: 10.1093/gerona/glz270. PubMed PMID: 31755896; PubMed Central PMCID: PMC7164522.
  123. Mahorter SS, Knerr S, **Bowles EJA**, Wernli KJ, Gao H, Schwartz MD, O'Neill SC. Prior breast density awareness, knowledge, and communication in a health system-embedded behavioral intervention trial. *Cancer*. 2020 Apr 15;126(8):1614-1621. PubMed PMID: 31977078; PubMed Central PMCID: PMC7103492.
  124. Buist DSM, Ichikawa L, Wernli KJ, Lee CI, Henderson LM, Kerlikowske K, **Bowles EJA**, Miglioretti DL, Specht J, Rauscher GH, Sprague BL, Onega T, Lee JM. Facility variability in examination indication among women with prior breast cancer: implications and the need for standardization. *J Am Coll Radiol*. 2020 Jun; 17(6); 755-764. PubMed PMID: 32004483; PubMed Central PMCID: PMC7275918.
  125. Wang R, Miglioretti DL, Marlow EC, Kwan ML, Theis MK, **Bowles EJA**, Greenlee RT, Rahm AK, Stout NK, Weinmann S, Smith-Bindmann R. Trends in imaging in for suspected pulmonary embolism across US healthcare systems, 2004-2016. *JAMA Network Open*. 2020;3(11):e226930. doi: 10.1001/jamanetworkopen.2020.26930. PubMed PMID: 33216141; PubMed Central PMCID: PMC7679949.
  126. Wernli KJ, **Bowles EJA**, Knerr S, Leppig KA, Ehrlich K, Gao H, Schwartz MD, O'Neill SC. Characteristics Associated with Participation in ENGAGED 2 - A Web-based Breast Cancer Risk Communication and Decision Support Trial. *Perm J*. 2020 Dec;24:1-4. doi: 10.7812/TPP/19.205. PMID: 33482952; PMCID: PMC7849258.
  127. Wernli KJ, Knerr S, Li T, Leppig K, Ehrlich K, Farrell D, Gao H, **Bowles EJA**, Graham AL, Luta G, Jayasekera J, Mandelblatt JS, Schwartz MD, O'Neill SC. Effect of Personalized Breast Cancer Risk Tool on Chemoprevention and Breast Imaging: ENGAGED-2 Trial. *JNCI Cancer Spectr*. 2021 Jan 14;5(1):pkaa114. doi: 10.1093/jncics/pkaa114. PMID: 33554037; PMCID: PMC7853161.
  128. Abubakar M, Fan S, **Bowles EJA**, Widemann L, Duggan MA, Pfeiffer RM, Falk RT, Lawrence S, Richert-Boe K, Glass AG, Kimes TM, Figueroa JD, Rohan TE, Gierach GL. Relation of Quantitative Histologic and Radiologic Breast Tissue Composition Metrics With Invasive Breast Cancer Risk. *JNCI Cancer Spectr*. 2021 Feb 6;5(3):pkab015. doi: 10.1093/jncics/pkab015. PMID: 33981950; PMCID: PMC8103888.
  129. Marlow EC, Ducore J, Kwan ML, Cheng SY, **Bowles EJA**, Greenlee RT, Pole JD, Rahm AK, Stout NK, Weinmann S, Smith-Bindman R, Miglioretti DL. Leukemia Risk in a Cohort of 3.9 Million

- Children with and without Down Syndrome. *J Pediatr.* 2021 Jul;234:172-180.e3. doi: 10.1016/j.jpeds.2021.03.001. Epub 2021 Mar 6. PMID: 33684394; PMCID: PMC8238875.
130. Sprague BL, Lowry KP, Miglioretti DL, Alsheik N, **Bowles EJA**, Tosteson ANA, Rauscher G, Herschorn SD, Lee JM, Trentham-Dietz A, Weaver DL, Stout NK, Kerlikowske K. Changes in Mammography Utilization by Women's Characteristics during the First 5 Months of the COVID-19 Pandemic. *J Natl Cancer Inst.* 2021 Mar 29:djab045. doi: 10.1093/jnci/djab045. Epub ahead of print. PMID: 33778894; PMCID: PMC8083761.
  131. Feigelson HS, Bodelon C, Powers JD, Curtis RE, Buist DSM, Veiga LHS, **Bowles EJA**, Berrington de González A, Gierach GL. Body Mass Index and Risk of Second Cancer among Women with Breast Cancer. *J Natl Cancer Inst.* 2021 Apr 5:djab053. doi: 10.1093/jnci/djab053. Epub ahead of print. PMID: 33823007.
  132. **Bowles EJA**, Miglioretti DL, Kwan ML, Bartels U, Furst A, Cheng SY, Lau C, Greenlee RT, Weinmann S, Marlow EC, Rahm AK, Stout NK, Bolch WE, Theis MK, Smith-Bindman R, Pole JD. Long-term medical imaging use in children with central nervous system tumors. *PLoS One.* 2021 Apr 21;16(4):e0248643. doi: 10.1371/journal.pone.0248643. PMID: 33882069; PMCID: PMC8059842.
  133. Lee JM, Ichikawa LE, Wernli KJ, **Bowles EJA**, Specht JM, Kerlikowske K, Miglioretti DL, Lowry KP, Tosteson ANA, Stout NK, Houssami N, Onega T, Buist DSM. Digital Mammography and Breast Tomosynthesis Performance in Women with a Personal History of Breast Cancer, 2007-2016. *Radiology.* 2021 Aug;300(2):290-300. doi: 10.1148/radiol.2021204581. Epub 2021 May 18. PMID: 34003059; PMCID: PMC8328154.
  134. Weinmann S, Francisco MC, Kwan ML, **Bowles EJA**, Rahm AK, Greenlee RT, Stout NK, Pole JD, Kushi LH, Smith-Bindman R, Miglioretti D. Positive predictive value and sensitivity of ICD-9-M codes for identifying pediatric leukemia. *Pediatric Blood & Cancer.* 2022 Feb;69(2):e29383. doi: 10.1002/pbc.29383. PMID 34773439.
  135. Lowry KP, Bissell M, Miglioretti DL, Kerlikowske K, Alsheik N, Macarol T, **Bowles EJA**, Buist DSM, Tosteson ANA, Henderson L, Herschorn SD, Wernli KJ, Weaver DL, Stout NK, Sprague BL. Breast biopsy recommendations and breast cancers diagnosed during the COVID-19 pandemic. *Radiology.* 2022 May;303(2):287-294. PMID: 34665032
  136. **Bowles EJA**, O'Neill SC, Li T, Knerr S, Mandelblatt JS, Schwartz MD, Jayasekera J, Leppig K, Ehrlich K, Farrell D, Gao H, Graham AL, Luta G, Wernli KJ. Effect of a randomized trial of a web-based intervention on patient-provider communication about breast density. *Journal of Women's Health.* 2021 Nov;30(11):1529-1537. PMID: 34582721.
  137. Conley CC, Wernli KJ, Knerr S, Li T, Leppig K, Ehrlich K, Farrell D, Gao H, **Bowles EJA**, Graham AL, Luta G, Jayasekera J, Mandelblatt JS, Schwartz MD, O'Neill SC. Using Protection Motivation Theory to predict intentions for breast cancer risk management: Intervention mechanisms from a randomized controlled trial. *Journal of Cancer Education.* Epub 2021 Nov 23. PMID:34813048
  138. **Bowles EJA**, Ramin C, Buist DSM, Feigelson HS, Weinmann S, Veiga L, Bodelon C, Curtis RE, Vo JB, Gonzalez AB, Gierach GL. Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016. *Breast Cancer Research and Treatment.* 2022 May;193(1):203-216. PMID: 35275285.
  139. Kwan ML, Miglioretti DL, **Bowles EJA**, Weinmann S, Greenlee RT, Stout NK, Rahm AK, Alber SA, Pequeno P, Moy LM, Stewart C, Fong C, Jenkins CL, Kohnhorst D, Luce C, Mor JM, Munneke JR, Prado Y, Buth G, Cheng SY, Deosaransingh KA, Francisco M, Lakoma M, Martinez YT, Theis MK, Marlow EC, Kushi LH, Duncan JR, Bolch WE, Pole JD, Smith-Bindman R. Quantifying cancer risk from exposures to medical imaging in the Radiation-Induced Cancers (RIC) study: Research methods and cohort profile. *Cancer Causes & Control.* 2022 May;33(5):711-726. PMID: 35107724.
  140. Abubakar M, Mullooly M, Nyante S, Pfeiffer RM, **Bowles EJA**, Cora R, Bodelon C, Butler E, Butcher D, Sternberg L, Troester M, Weinmann S, Sherman M, Glass AG, Berrington de Gonzalez A, Gierach GL. Mammographic Density Decline As a Prognostic Marker of Tamoxifen

- Response by ER-Positive Breast Cancer Subtype. *JNCI Cancer Spectrum*. 2022 May 2;6(3):pkac028. PMID: 35583138
141. \*Haas CB, **Aiello Bowles EJ**, Lee JM, Specht J, Buist DSM. Accuracy of tumor registry versus pharmacy dispensings for breast cancer adjuvant endocrine therapy. *Cancer Causes Control*. 2022 Sep;33(9):1145-1153. PMID:35796845
  142. Ramin C, Gierach G, Abubakar M, Veiga L, Vo J, Curtis R, **Bowles E**, Feigelson H, Buist D, Berrington de Gonzalez A, Bodelon C. The influence of treatment on hormone receptor subgroups and breast cancer-specific mortality within integrated healthcare systems. *Cancer Causes & Control*. 2022 Jul; 33(7):1019-1023. PMID: 35583697.
  143. Sarma EA, Thompson MJ, **Bowles EJA**, Burnett-Hartman AN, Hubbard RA, Yu O, Chubak J. Patient and Tumor Characteristics of Screening-Age Adults Diagnosed with Screen-Detected versus Symptomatic Colon Cancer. *Colorectal Dis*. 2022 Jun 23. [epub ahead of print] PMID:35739634
  144. Lawson MB, Bissell MCS, Miglioretti DL, Eavey J, Chapman CH, Mandelblatt JS, Onega T, Henderson LM, Rauscher GH, Kerlikowske K, Sprague BL, **Bowles EJA**, Gard CC, Parsian S, Lee CI. Multilevel predictors of time to biopsy after abnormal screening mammography by race and ethnicity. *JAMA Oncology*. 2022 Aug 1;8(8):1115-1126. PMID:35737381
  145. Nyante SJ, Abraham L, **Aiello Bowles EJ**, Lee CI, Kerlikowske K, Miglioretti DL, Sprague BL, Henderson LM. Diagnostic mammography performance across racial and ethnic groups in a national network of community-based breast imaging facilities. *Cancer Epidemiol Biomarkers Prev*. 2022 Jul 1; 31(7):1324-1333. PMID: 35712862.
  146. Veiga LHS, Vo JB, Curtis RE, Mille MM, Lee C, Ramin C, Bodelon C, **Aiello Bowles EJ**, Buist DSM, Weinmann S, Feigelson HS, Gierach GL, Berrington de Gonzalez A. Treatment-related thoracic soft tissue sarcomas in two US cohorts of breast cancer survivors. *Lancet Oncology* 2022 Oct 11;S1470-2045(22):00561-7. PMID: 36240805 [epub ahead of print]
  147. Lowry KP, Ichikawa L, Hubbard RA, Buist DSM, **Bowles EJA**, Henderson LM, Kerlikowske K, Specht JM, Sprague BL, Wernli KJ, Lee JM. Variation in second breast cancer risk after primary invasive cancer by time since primary cancer diagnosis and estrogen receptor status. *Cancer*. 2023 Apr 15;129(8):1173-1182. PMID: 36789739
  148. Su YR, Buist DSM, Lee JM, Ichikawa L, Miglioretti DM, **Bowles EJA**, Wernli KJ, Kerlikowske K, Tosteson ANA, Lowry KP, Henderson L, Sprague BL, Hubbard RA. Performance of statistical and machine learning risk prediction models for breast cancer surveillance benefits and failures. *Cancer Epidemiol Biomarkers Prev*. 2023 Jan 25:EPI-22-0677. doi: 10.1158/1055-9965.EPI-22-0677. Online ahead of print. PMID: 36697364
  149. Lee CI, Abraham L, Miglioretti DL, Onega T, Kerlikowske K, Lee JM, Sprague BL, Tosteson ANA, Rauscher GH, **Bowles EJA**, diFlorio-Alexander RM, Henderson LM; National Performance Benchmarks for Screening Digital Breast Tomosynthesis: Update from the Breast Cancer Surveillance Consortium. *Breast Cancer Surveillance Consortium. Radiology*. 2023 Apr 11:222499. doi: 10.1148/radiol.222499. Online ahead of print. PMID: 37039687
  150. Sprague BL, Chen S, Miglioretti DL, Gard CC, Tice JA, Hubbard RA, **Aiello Bowles EJ**, Kaufman PA, Kerlikowske K. Cumulative 6-Year Risk of Screen-Detected Ductal Carcinoma In Situ by Screening Frequency. *JAMA Netw Open*. 2023 Feb 1;6(2):e230166. doi: 10.1001/jamanetworkopen.2023.0166.PMID: 36808238
  151. Sprague BL, Coley RY, Lowry KP, Kerlikowske K, Henderson LM, Su YR, Lee CI, Onega T, **Bowles EJA**, Herschorn SD, diFlorio-Alexander RM, Miglioretti DL. Digital breast tomosynthesis versus digital mammography screening performance on successive screening rounds. *Radiology*. 2023 Jun:307(5)e223142. doi:10.1148/radiol.223142.
  152. Ramin C, Veiga LHS, Vo JB, Curtis RE, Bodelon C, **Bowles EJA**, Buist DSM, Weinmann S, Feigelson HS, Gierach GL, Berrington de Gonzalez A. Risk of second primary cancer among breast cancer patients in the Kaiser Breast Cancer Survivors Cohort. *Breast Cancer Research*. 2023 May 3;25(1):50. doi:10.1186/s13085-023-01647-y.

153. Kerlikowske K, Bissell MCS, Sprague BL, Tice JA, Tossas KY, **Bowles EJA**, Ho TQ, Keegan THM, Miglioretti DL. Impact of BMI on prevalence of dense breasts by race and ethnicity. *Cancer Epidemiology Biomarkers and Prevention*. 2023 Jun 7:OF1-OF7. doi:10.1158/1055-9965.EPI-23-0049. Online ahead of print.
154. Lee JM, Ichikawa L, Wernli KJ, **Bowles EJA**, Specht JM, Kerlikowske K, Miglioretti DL, Lowry KP, Tosteson ANA, Stout NK, Houssami N, Onega T, Buist DSM. Impact of Surveillance Mammography Intervals Less Than One Year on Performance Measures in Women With a Personal History of Breast Cancer. *Korean Journal of Radiology* 2023 Aug;24(8):729-739.
155. Nyante SJ, Abraham L, **Aiello Bowles EJ**, Lee CI, Kerlikowske K, Miglioretti DL, Sprague BL, Henderson LM for the Breast Cancer Surveillance Consortium. Racial and ethnic variation in diagnostic mammography performance among women reporting a breast lump. *Cancer Epidemiol Biomarkers Prev*. 2023 Jul 13;EPI-23-0289. Online ahead of print.
156. Onega T, Abraham L, Lee CI, Henderson LM, Miglioretti DL, Kerlikowske K, Tosteson ANA, Weaver D, Sprague BL, **Aiello Bowles EJ**, diFlorio RM. Digital mammography and digital breast tomosynthesis for detecting invasive lobular and ductal carcinoma. *Breast Cancer Research and Treatment*. 2023 Sep 11. Online ahead of print.
157. Marlow E, Ducore J, Kwan ML, **Bowles EJA**, Greenlee RT, Pole JD, Rahm AK, Stout NK, Weinmann S, Smith-Bindman R, Miglioretti D. Medical imaging utilization and associated radiation exposure in children with Down syndrome. *PLOS One*. 2023 Sep 6;18(9)e0289957
158. Atakpa EC, Buist DSM, **Bowles EJA**, Cuzick J, Brentnall AR. Development and evaluation of a method to assess breast cancer risk using a longitudinal history of mammographic density: a cohort study. *Breast Cancer Research*. 2023 Nov 24. doi:10.1186/s13058-023-01744-y. Online ahead of print.
159. Kantor ED, O'Connell KO, Ergas IJ, Valice E, Roh JM, Bhimani J, Heon N, Griggs JJ, Lee J, **Bowles EJA**, Rivera DR, Kolevska T, Bandera EV, Kushi LH. Assessment of Breast Cancer Chemotherapy Dose Reduction in an Integrated Healthcare Delivery System. *Breast Cancer Research and Treatment*. 2024 Feb;203(3):565-574. PMID: 37923962.
160. **Aiello Bowles EJ**, Kroenke CH, Chubak J, Bhimani J, O'Connell K, Brandzel S, Valice E, Doud R, Theis MK, Roh JM, Heon N, Persaud S, Griggs JJ, Bandera EV, Kushi LH, Kantor ED. Evaluation of algorithms using automated health plan data to identify breast cancer recurrences. *Cancer Epidemiology Biomarkers and Prevention*. 2024 Mar 1;33(3):355-364. PMID: 38088912.
161. Kessler LG, Comstock B, **Aiello Bowles EJ**, Mou J, Nash MG, Bravo P, Fleckenstein LE, Pflugeisen C, Gao H, Winer R, Ornelas IJ, Smith C, Neslund-Dudas C, Shetty P. Protocol to Measure Validity and Reliability of Colorectal, Breast, Cervical and Lung Cancer Screening Questions from the 2021 National Health Interview Survey: Methodology and Design. *PLOS ONE* 2024 Mar 4;19(3):e00297773. PMID: 38437207.
162. Bhimani J, O'Connell K, Ergas IJ, Foley M, Gallagher GB, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke CH, Laurent CA, Liu R, Nakata KG, Persaud S, Rivera DR, Roh JM, Tabatabai S, Valice E, **Bowles EJA**, Bandera EV, Kushi LH, Kantor ED. Methodology for using real-world data from electronic health records to assess chemotherapy administration in women with breast cancer. *JCO Clinical Cancer Informatics*. 2024 Apr;8:e2300209. PMID: 38635936.
163. Hubbard RA, Su YR, **Bowles EJA**, Ichikawa L, Kerlikowske K, Lowry KP, Miglioretti DL, Tosteson ANA, Wernli KJ, Lee JM. Predicting five-year cumulative absolute risk of interval second breast cancer in women with a personal history of breast cancer. *JNCI*. 2024 Mar 11:djae063. doi: 10.1093/jnci/djae063. Online ahead of print.
164. **Aiello Bowles EJ**, Ramin C, Vo JB, Feigelson HS, Gander JC, Veiga LHS, Bodelon C, Curtis RE, Brandt C, Berrington de Gonzalez A, Gierach GL. Endocrine therapy initiation among women diagnosed with ductal carcinoma *in situ* from 2001-2018. *Breast Cancer Research and Treatment*. 2024 Dec;208(3):577-587. doi: 10.1007/s10549-024-07453-0. PMID:39148003

165. Mullooly M, Shaoqi F, Pfeiffer RM, **Aiello Bowles E**, Duggan MA, Falk RT, Richert-Boe K, Glass AG, Kimes TM, Figueroa JD, Rohan TE, Abubakar M, Gierach GL. Temporal changes in mammographic breast density and breast cancer risk among women with benign breast disease. *Breast Cancer Research* 2024 Mar 26;26(1):52. doi: 10.1186/s13058-024-01764-2.
166. Bhimani J, O'Connell K, Persaud S, Blinder V, Burganowski R, Ergas IJ, Foley M, Gallagher GB, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke CH, Laurent CA, Liu R, Nakata KG, Rivera DR, Roh JM, Tabatabai S, Valice E, Bandera EV, **Bowles EJA**, Kushi LH, Kantor ED. Patient characteristics associated with delayed time to adjuvant chemotherapy among women treated for stage I-IIIa breast cancer. *International Journal of Cancer*. 2024 Jul 6. doi: 10.1002/ijc.35053. Online ahead of print.
167. Bhimani J, O'Connell K, Ergas IJ, Foley M, Gallagher GB, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke CH, Laurent CA, Lie R, Nakata KG, Persaud S, Rivera DR, Roh JM, Tabatabai S, Valice E, **Bowles EJA**, Bandera EV, Kushi LH, Kantor ED. Trends in chemotherapy use for early-stage breast cancer from 2006-2019. *Breast Cancer Research* 2024 Jun 13;26(1):101. doi: 10.1186/s13058-024-01822-9.
168. Vo JB, Ramin C, Veiga LHS, Brandt C, Curtis RE, Bodelon C, Barac A, Roger VL, Feigelson HS, Buist DSM, **Aiello Bowles EJ**, Gierach GL, Berrington de Gonzalez A. Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in U.S. breast cancer survivors. *JNCI*. 2024 Aug 1;116(8):1384-1394. doi: 10.1093/jnci/djae107.
169. Bhimanji J, O'Connell K, Persaud S, Blinder V, Burganowski-Doud R, Ergas IJ, Gallagher GB, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke CH, Laurent CA, Liu R, Nakata KG, Rivera DR, Roh JM, Tabatabai S, Valice E, Bandera EV, **Bowles EJA**, Kushi LH, Kantor ED. Patient characteristics associated with intended non-guideline chemotherapy in women with stage I-IIIa breast cancer. *CEBP*. 2024 Oct -2;33(10):1286-1297. doi: 10.1158/1055-9965.EPI-24-0360. PMID: 39051907
170. Bhimanji J, O'Connell K, Persaud S, Blinder V, Burganowski R, Ergas IJ, Foley M, Gallagher GB, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke CH, Laurent CA, Liu R, Nakata KG, Rivera DR, Roh JM, Tabatabai S, Valice E, Bandera EV, **Bowles EJA**, Kushi LH, Kantor ED. The landscape of NCCN-guideline concordant chemotherapy in stage I-IIIa breast cancer in an integrated healthcare delivery system. *Breast Cancer Research and Treatment*. 2024 Aug 16. doi: 10.1007/s10549-024-07433-4. Online ahead of print.
171. Miglioretti DL, Abraham L, Sprague BL, Lee CI, Bissell MCS, Ho TQH, **Bowles EJA**, Henderson LM, Hubbard RA, Tosteson ANA, Kerlikowske K. Association between false-positive results and return to screening mammography in the Breast Cancer Surveillance Consortium. *Annals of Internal Medicine* 2024 Oct;177(10):1297-1307. doi: 10.7326/M24-0123
172. Foster VM, Trentham-Dietz A, Stout NK, Lee CI, Ichikawa LE, Eavey J, Henderson L, Miglioretti DL, Tosteson ANA, **Bowles EA**, Kerlikowske K, Sprague BL. Supplemental breast cancer screening after negative mammography in U.S. women with dense breasts. *JNCI* 2024 Oct 30; doi:10.1093/jnci/djae272. Online ahead of print.
173. Fernandes-Taylor S, **Bowles E**, Venkatesh M, Burganowski Doud R, Kresbach C, Arroyo N, Hanlon B, Chen A, Davies L, Francis D. Differential ultrasound rates explain sex disparities in thyroid cancer. *Thyroid* 2024 Dec;34(12):1531-1539. Doi:10.1089/thy.2024.2344. PMID: 39607408
174. Lawson MB, Zhu W, Miglioretti DL, Onega T, Henderson LM, Rauscher LM, Kerlikowske K, Sprague BL, **Bowles EJA**, O'Meara ES, Tosteson ANA, di-Florio-Alexander RM, Hubbard RA, Lee JM, Lee CI. Disparities in standard-of-care, advanced, and same-day diagnostic services among patients with abnormal screening mammography. *Radiology*. 2025 Feb;314(2):e241673. Doi:10.1148/radiol.241673 Online ahead of print.
175. Wang P, O'Connell K, Bhimani J, Blinder V, Burganowski R, Ergas IJ, Gallagher GB, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke CH, Laurent CA, Liu R, Nakata KG, Persaud S, Rivera DR, Roh JM, Tabatabai S, Valice E, Bandera EV, Kushi LH, **Aiello Bowles EJ**, Kantor ED. A

- methodologic approach to defining comorbidities in a cohort of cancer patients: an example in the Optimal Breast Cancer Chemotherapy Dosing Study. *JCO Clinical Cancer Informatics*. 2025 Feb;9:e2400231. Doi:10.1200/CCI-24-00231. Online ahead of print.
176. **Bowles EJA**, Gao H, Fleckenstein LE, Bravo P, Nash MG, Comstock B, Neslund-Dudas C, Mou J, Kessler LG. Accuracy of self-reported exam indications for breast cancer screening. *JNCI Cancer Spectr*. 2025 May 5: pkaf046. Doi: 10.1093/jncics/pkaf046. Online ahead of print.
  177. Henderson LM, Zhu W, Onega T, Kerlikowske K, Miglioretti DL, **Bowles EJA**, Sprague BL, Weaver DL, Tosteson ANA, Lee CI. Diagnostic management pathways for workup of abnormal screening with digital mammography versus digital breast tomosynthesis. *J Am Coll Radiol*. 2025 Apr 9:S1546-1440(25)00207-8. Doi: 10.1016/j.jacr.2025.04.005. Online ahead of print.
  178. Bhimani J, Wang P, Gallagher GB, O'Connell K, Blinder V, Burganowski R, Ergas IJ, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke C, Laurent CA, Liu R, Nakata KG, Persaud S, Rivera DR, Roh JM, Tabatabai S, Valice E, Bandera EV, **Aiello Bowles EJ**, Kushi L, Kantor E. Patient factors and modifications to intended chemotherapy for women with stage I-IIIa breast cancer. *International Journal of Cancer*. 2025 Oct 1; 157(7):1342-1353. Doi: 10.1002/ijc.35494. *Epib* 2025 Jun 2.
  179. Bhimani J, Wang P, Gallagher GB, O'Connell K, Blinder V, Burganowski R, Ergas IJ, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke C, Laurent CA, Liu R, Nakata KG, Persaud S, Rivera DR, Roh JM, Tabatabai S, Valice E, Bandera EV, **Aiello Bowles EJ**, Kushi L, Kantor E. Patient characteristics associated with conventional schedule vs dose dense chemotherapy in women with stage I-IIIa breast cancer, *Breast Cancer Research and Treatment*. 2025 Aug;213(1):115-126. Doi: 10.1007/s10549-025-07764-w. *Epub* 2025 Jul 6.
  180. Stewart C, Alber SA, Mahendra M, Kofler C, Tran T, Domal S, **Bowles EJA**, Weinmann S, Greenlee RT, Stout NK, Pequeno P, Moy LM, Duncan JR, Pole JD, Bolch WE, Kwan ML, Miglioretti DM, Smith-Bindman R. Quantifying and contextualizing radiation doses in common pediatric medical imaging examinations. *Journal of Pediatrics: Clinical Practice*. 2025 Jul 23:17:200166. Doi: 10.1016/j.jpdc.2025.200166. *eCollection* 2025 Sep. PMID: 40822255
  181. Smith-Bindman R, Alber SA, Kwan ML, Pequeno P, Bolch WE, **Bowles EJA**, Greenlee RT, Stout NK, Weinmann S, Moy LM, Stewart C, Francisco M, Kofler C, Duncan JR, Ducore J, Mahendra M, Pole JD, Miglioretti DL. Medical imaging and pediatric and adolescent hematologic risk. *New England Journal of Medicine*. 2025 Sept 17:10.1056/NEJMoa2502098 doi:10.1056/NEJMoa2502058 Online ahead of print. PMID: 40961449
  182. Lee C, Borrego D, Veiga LHS, Smith SA, Howell RM, Curtis R, Mille MM, Feigelson HS, Weinmann S, **Aiello Bowles EJ**, Buist DSM, Vo JB, Gierach GL, Berrington de Gonzalez A. Trends in dose to the contralateral breast from breast cancer radiotherapy in the United States. *Radiation Research*. 2025 Sep 8. doi: 10.1667/RADE-25-00069.1. Online ahead of print.
  183. Gunn CM, Boyer N, Sheikh S, Lee JM, Woloshin S, Specht JM, Hubbard RA, **Aiello Bowles EJ**, Su YR, Tosteson ANA. Patient and physician perspectives on a risk prediction tool to support breast cancer surveillance decision-making. *Medical Decision Making*. 2025 Oct 21: 272989X251379888. doi: 10.1177/0272989X251379888. Online ahead of print.
  184. Bhimani J, O'Connell K, Gallagher GB, Blinder V, Burganowski R, Ergas IJ, Griggs JJ, Heon N, Jinna S, Kolevska T, Kotsurovskyy Y, Kroenke C, Laurent CA, Liu R, Nakata KG, Persaud S, Roh JM, Tabatabai S, Valice E, Wang P, Bandera EV, **Aiello Bowles EJ**, Kushi L, Kantor E. Understanding the association between body mass index and chemotherapy dose reductions in women treated for stage I-IIIa breast cancer. *NPJ Breast Cancer*. 2025 Oct 29;11(1):119. doi: 10.1038/s41523-025-00833-9.
  185. **Aiello Bowles EJ**, O'Connell K, Bhimani J, Gallagher GB, Blinder VS, Doud RB, Ergas IJ, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke CH, Laurent CA, Liu R, Nakata KG, Persaud S, Rivera DR, Roh JM, Tabatabai S, Valice E, Wang P, Bandera EV, Kushi LH, Kantor ED. Associations between age and chemotherapy dose reductions in women with stage I-IIIa breast cancer. *JNCI*. 2025 Nov 3; djaf314. Doi: 10.10093/jnci/djaf314. Online ahead of print.

186. Veiga LHS, Gierach GL, Smith SA, Howell RM, Mille MM, Curtis RE, Ramin C, Bodelon C, Feigelson HS, **Aiello Bowles EJ**, Buist DSM, Weinmann S, Vo JB, Lee C, Berrington de Gonzalez A, Saha M. Contralateral breast cancer after radiotherapy and hormone therapy in two cohorts of US breast cancer survivors. *British Journal of Cancer*. 2025 Nov 14. doi: 10.1038/s41416-025-03240-w. Online ahead of print.
187. Wang P, O'Connell K, Bhimani J, Blinder V, Burganowski R, Ergas IJ, Gallagher G, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke C, Laurent CA, Liu R, Nakata KG, Persaud S, Roh JM, Tabatabai S, Valice E, Sampathkumar Y, Bandera EV, Kushi L, Kantor E, **Aiello Bowles EJ**. Evaluation of methods to identify chemotherapy-related hematologic toxicities in real-world settings. *Int J Cancer*. 2025 Nov 28. Doi: 10.1002/ijc.70266. Online ahead of print
188. Mann H, Zhang Yi, Arroyo N, Adil A, Zhang Ya, Alagoz O, Fernandes-Taylor S, **Aiello Bowles EJ**, Davies L, Francis DO. Impact of COVID-19 Restrictions on Thyroid Cancer Diagnoses in a Comprehensive Cancer Center (2017-2023). *PLOS One*. 2026 Jan 15;21(1):e0340347. doi: 10.1371/journal.pone.0340347. eCollection 2026. PMID: 41538388. PMCID: PMC12806843
- 189.

#### Accepted peer-reviewed papers in press

1. Sampathkumar Y, Zakaria Z, O'Connell K, Bhimani J, Blinder V, Burganowski R, Ergas IJ, Gallagher GB, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke CH, Laurent CA, Liu R, Nakata KG, Persaud S, Roh JM, Tabatabai S, Valice E, Bandera EV, **Aiello Bowles EJ**, Kushi LH, Kantor ED. Clinician and facility factors associated with non-guideline chemotherapy in early-stage breast cancer JCO Oncology practice (in press).
2. Francis DO, Davies L, Zhang Y, Arroyo N, Fernandes-Taylor S, Nordby P, Venkatesh M, **Bowles E**, Alagoz O. Overdiagnosis of Papillary Thyroid Cancer: current state and mitigation. *JAMA Network Open* (in press).
3. Bhimani J, Wang P, Gallagher GB, O'Connell K, Blinder V, Burganowski R, Ergas IJ, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke C, Laurent CA, Liu R, Nakata KG, Persaud S, Rivera DR, Roh JM, Tabatabai S, Valice E, Bandera EV, **Aiello Bowles EJ**, Kushi L, Kantor E. The landscape of chemotherapy modifications among women treated for stage I-IIIa breast cancer. *Cancer*. (in press).
4. Monroy Iglesias M, O'Connell K, Bhimani J, Blinder V, Burganowski R, Ergas IJ, Gallagher G, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke C, Laurent CA, Liu R, Nakata KG, Persaud S, Roh JM, Sampathkumar Y, Tabatabai S, Valice E, **Aiello Bowles EJ**, Bandera EV, Kushi L, Kantor E. Initial chemotherapy dose reductions and subsequent treatment delivery in early-stage breast cancer. *Cancer* (in press).
5. Kessler LG, Comstock B, **Aiello Bowles EJ**, Mou J, Nash MG, Bravo P, Fleckenstein LE, Pflugeisen C, Gao H, Winder RL, Ornelas IJ, Smith C, Neslund-Dudas C, Shetty P, Raghavan UG. Measuring the validity of survey questions on breast, cervical, colorectal, and lung cancer screening. *American Journal of Epidemiology* (in press).
- 6.

#### Non-refereed articles

1. Stern S and **Aiello E**. Success of Environmental Laws Hinges on Public Perception. *The Los Angeles Times*. Oct 22, 2000.
2. Onitilo AA, Engel JM, James TA, **Bowles EJA**, McCahill LE, Feigelson HS. Reply to: Should initial mastectomy rates increase? *J Am Coll Surg*. 2013 Nov;217(5):960-2. doi: 10.1016/j.jamcollsurg.2013.07.396.

3. Sprague BL, Trentham-Dietz A, Hedman CJ, Wang J, Hemming JD, Hampton JM, Buist DS, **Bowles EJ**, Burnside ES. Author's response. *Breast Cancer Res.* 2013;15(5):403. PubMed PMID: 24592439.

#### Book chapters:

1. Breast Imaging. Eds Lee CI, Lehman CD, Bassett LW. New York, NY: Oxford University Press 2018. Chapter 2: "Breast Cancer Screening: Evidence and Recommendations. Karen J Wernli and **Erin J Bowles**, pp 14-17.

#### Published technical reports

1. Henrikson NB, **Aiello Bowles EJ**, Blasi PR, Morrison CC, Nguyen M, Pillarisetty VG, Lin JS. Screening for Pancreatic Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality (US); 2019. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK563783/>
2. Lin JS, **Aiello Bowles EJ**, Williams SB, Morrison CC. Screening for Thyroid Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality (US); 2017. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK447370/>

#### Published abstracts from professional conferences

1. Irwin ML, **Aiello E**, Gilliland F, McTiernan A, Baumgartner R, Bernstein L, Ballard-Barbash R. The Association between Physical Activity Levels and Mammographic Breast Density in pre- and post-menopausal women: The Health, Eating, Activity, and Lifestyle (HEAL) Study. *Cancer Epidemiology, Biomarkers and Prevention* 2003; 12(11):1284s-1285s.
2. **Aiello E**, Taplin S, Reid R, Paschall M, Seger D, Kamel H, Tufano J, Ballard-Barbash R. Electronic Data Collection from Patients on Breast Cancer Risk Factor Information in a Mammography Setting. *The American Journal of Managed Care* 2004; 10(9):651.
3. **Aiello EJ**, Buist DS, White E. Association between breast density and hormone therapy modified by breast cancer risk factors. *Cancer Epidemiology, Biomarkers and Prevention* 2004; 13(11):1972s-1928s.
4. Welsh ML, **Aiello EJ**, Anderson ML, Buist DSM. Population-based estimates of the relation between family history and breast cancer risk. *American Journal of Epidemiology* 2007; 165(11):Abstract 227-S.
5. Sprague B, Trentham-Dietz A, Heman C, Hemming J, Hampton J, Buist D, **Bowles EA**, Burnside E, Sisney G. The association of serum phthalates and parabens with mammographic breast density. *Cancer Epidemiol Biomarkers Prev.* 2011 Apr;20(4):718.

### **K. INVITED PRESENTATIONS**

#### Contributed Oral Presentations (as lead or coauthor)

1. "Duration and Type of Symptoms at the Time of a Mammogram". Breast Cancer Surveillance Consortium Meeting, Sugarbush, VT. October 2002.
2. "Group Health Cooperative Survey Automation Project". National Cancer Institute. February 2003.
3. "Developing automated alternatives for eliciting patient information for breast cancer screening surveillance". Breast Cancer Surveillance Consortium meeting, Portsmouth, NH. April 2003.
4. "Rate of breast cancer diagnoses among women with self-reported breast symptoms". Breast Cancer Surveillance Consortium meeting, Portsmouth, NH. April 2003.
5. "Use of Tablet PCs to Automate the Breast Screening Recruitment and Reminders (BSRR) Survey". Breast Cancer Surveillance Consortium meeting, Lake Tahoe, CA. October 2003.
6. "Censoring and cancer incidence: methodology". Breast Cancer Surveillance Consortium

- meeting, Vancouver, BC, Canada. April 2005.
7. "Comparison of ACR and BCSC definitions for screening and diagnostic mammograms." Breast Cancer Surveillance Consortium meeting, Vancouver, BC, Canada. April 2005.
  8. "Mammographic density and phase in the menstrual cycle." Group Health Cooperative, Breast Cancer Surveillance Scientific meeting, March 2005; and Breast Cancer Surveillance Consortium meeting, Vancouver, BC, Canada. April 2005.
  9. "Radiologist feedback project". Breast Cancer Surveillance Consortium Meeting, Seattle, WA. April 2008.
  10. "Patient-centered communication in cancer care: different perspectives on the quality of cancer care". Group Health Research Institute seminar, Seattle, WA July 2008.
  11. "Anesthesia and dementia risk", ACT Symposium, Seattle, WA August 4, 2014.
  12. "Cancer and subsequent dementia risk", ACT Symposium, Seattle, WA August 17, 2015.
  13. "How do we measure resilience to brain aging, dementia, and Alzheimer's disease?" ACT Symposium, Seattle, WA August 2017.
  14. "ACT Data Query Tool." ACT Symposium, Seattle, WA August 2017.
  15. "Endocrine therapy initiation among women diagnosed with DCIS from 2001-2018" Kaiser Breast Cancer Survivors Cohort meeting, Atlanta, GA, April 25, 2023.
  16. "Breast Cancer Screening Guidelines: Updated USPSTF Recommendations and KPWA Contributions....and why this is really cool!" KPWHRI All Institute meeting, June 1, 2023.
  17. "Evaluations of algorithms using automated health plan data to identify breast cancer recurrence." Kaiser Breast Cancer Survivors Cohort meeting, National Cancer Institute, October, 5 2023.
  18. "Geocoding the Kaiser Breast Cancer Survivors Cohort and linking to neighborhood-level SES." Kaiser Breast Cancer Survivors Cohort meeting, National Cancer Institute, October, 5 2023.
  19. "Breast Cancer Screening Guidelines: Updated Recommendations and Ongoing Research." Breast Cancer Awareness Month Lunch & Learn, Kautex, October 20, 2023.
  20. "Role of data and statistics in informing updated breast cancer screening guidelines." SeattleStatGROWS, Fred Hutchinson Cancer Center, July 24, 2024.
  21. "Measuring neighborhood- and facility-level drivers of health in the Breast Cancer Surveillance Consortium." Breast Cancer Surveillance Consortium meeting, May 12-13, 2025, Seattle, WA.
  22. "Race, ethnicity, and mammographic surveillance outcomes among women with a personal history of breast cancer." Breast Cancer Surveillance Consortium meeting, May 12-13, 2025, Seattle, WA.
  23. "Mammographic breast density as a predictive biomarker among women diagnosed with breast cancer." International Breast Density and Cancer Risk Assessment Workshop, June 4-6, 2025, Lihue, HI.
  24. "Accuracy of chemotherapy ascertainment in SEER among breast cancer survivors in a general community healthcare setting." American Society of Preventive Oncology annual meeting, Philadelphia, PA, April 6-8, 2025.
  25. "Risk of contralateral breast cancer after radiotherapy and hormonal therapy in two cohorts of US breast cancer survivors." International Society of Radiation Epidemiology and Dosimetry, Lyon, France, September 9-11, 2025.
  26. "Contralateral breast dose from breast cancer radiotherapy in the United States." International Society of Radiation Epidemiology and Dosimetry, Lyon, France, September 9-11, 2025.

## **L. OTHER PRESENTATIONS**

### Oral presentations

1. "The trustworthiness of administrative health plan data in chemotherapy research". HMO Research Network Meeting, Minneapolis, MN. April 2008.

2. "Chemotherapy associated with increased heart failure risk among women with breast cancer in the CRN." HMO Research Network meeting in Boston, MA, 2011.
3. "Anesthesia exposure and risk of dementia and Alzheimer's disease: a prospective study." HCSRN meeting, Atlanta, GA. April 2016.
4. "Creating a career path for the Learning Health System Workforce". HCSRN meeting, Milwaukee, WI, April 9-11, 2024.

#### Poster presentations

1. **Aiello EJ**, Tworoger SS, Ulrich CM, Rajan K, Fay M, McTiernan A. Little Association Between CYP17, CYP1B1, or COMT Polymorphisms and Steroid Sex Hormones in Post-Menopausal Breast Cancer Patients. 2002 Proceedings of the American Association for Cancer Research April 6-10, 2002 San Francisco, CA.
2. Palomares MR, **Aiello E**, Lehman CD, Gralow JR, McTiernan A. Mammographic breast density as a noninvasive surrogate marker of breast cancer risk modification: A comparison of density assessment methods. 2003 Proceedings of the American Association for Cancer Research April 5-9, 2003 Toronto, Ontario, Canada.
3. **Aiello E**, Taplin S, Reid R, Paschall M, Seger D, Kamel H, Tufano J, Ballard-Barbash R. Electronic Data Collection from Patients on Breast Cancer Risk Factor Information in a Mammography Setting. HMO Research Network meeting, Dearborn, MI, May 3-5, 2004.
4. **Aiello EJ**, Buist DSM, White E. Association between hormone therapy and breast density modified by breast cancer risk factors. American Association for Cancer Research: Frontiers in Cancer Prevention Research meeting, Seattle, WA, Oct. 16-19, 2004.
5. Crest AB, **Aiello EJ**, Anderson ML, Buist DSM. Varying levels of family history of breast cancer in relation to mammographic breast density. American Society of Preventive Oncology Annual Meeting, March 13-15, 2005, San Francisco, CA. (Poster presentation; 3<sup>rd</sup> place award).
6. Buist DSM, Newton KM, Reed S, Anderson ML, **Aiello EJ**, Palmer L, Seger D. Can short-term hormone therapy (HT) cessation before mammography decrease breast density and improve mammography performance? A randomized trial – the READ study. Era of Hope 2005 – Department of Defense Breast Cancer Research Program meeting. June 8-11, 2005, Philadelphia, PA.
7. Buist DSM, **Aiello EJ**, Miglioretti DL, Mahoney L, White E. Mammographic breast density, dense area, and breast area by phase in the menstrual cycle. San Antonio Breast Cancer Symposium, December 8-11, 2005, San Antonio, TX.
8. **Aiello EJ**, Geiger AM, Pardee R, Buist DSM, Hart G, Greene SM, Lamerato L, Field T, Wagner E. Diffusion of Aromatase Inhibitors for Breast Cancer. American Society of Preventive Oncology Annual Meeting, February 27-28, 2006, Bethesda, MD. (Poster presentation, 1<sup>st</sup> place award).
9. **Aiello EJ**, Geiger AM, Pardee R, Buist DSM, Hart G, Greene SM, Lamerato L, Field T, Wagner E. Diffusion of Aromatase Inhibitors for Breast Cancer. International Society of Pharmacoepidemiology meeting, August 24-26, 2006, Lisbon, Portugal.
10. **Aiello EJ**, Buist, DSM, Haneuse S, Elmore, JG. Reducing Delays in Diagnosis – Characteristics of Women with Timely Follow-up after and Abnormal Mammogram. American Society of Preventive Oncology Annual Meeting, March 1-4, 2007, Houston, TX; and HMO Research Network meeting, Portland, OR, March 19-21, 2007.
11. Buist DSM, **Aiello EJ**, Haneuse S, Elmore JG. Falling through the Cracks – Characteristics of Women without Follow-up after an Abnormal Mammogram. American Society of Preventive Oncology Annual Meeting, March 1-4, 2007, Houston, TX; and HMO Research Network meeting, Portland, OR, March 19-21, 2007.
12. **Aiello EJ**, Tuzzio L, Wiese C, Kirlin B, Greene SM, Wagner EH. Developing a Model for High Quality Cancer Care – Results from Expert Interviews. HMO Research Network meeting, Portland, OR, March 19-21, 2007.

13. **Aiello EJ**, Tuzzio L, Wiese C, Kirlin B, Greene SM, Wagner EH. Developing a Model for High Quality Cancer Care – Results from Community Focus Groups. HMO Research Network meeting, Portland, OR, March 19-21, 2007.
14. Greene SM, Kirlin B, Tuzzio L, **Aiello EJ**, Wagner EH. Developing a Model for High Quality Cancer Care – Results from a Literature Review. HMO Research Network meeting, Portland, OR, March 19-21, 2007.
15. Tuzzio L, Kirlin B, **Aiello EJ**, Greene SM, Wagner EH. Developing a Model for High Quality Cancer Care – Results from Visiting Organizations in Three Communities. HMO Research Network meeting, Portland, OR, March 19-21, 2007.
16. Tuzzio L, **Aiello Bowles EJ**, Altschuler A, Williams AE, Ritzwoller DP, Nekhlyudov L. The Feasibility of a Feasibility Study: Using the VDW to Assess the Diffusion of Ovarian Cancer Treatment. HMO Research Network meeting, Minneapolis, MN, April 13-16, 2008.
17. **Aiello Bowles EJ**, Anderson ML, Reed SD, Newton KM, Fitzgibbons ED, Seger D, Buist DSM. Tolerance for short-term hormone therapy suspension related to mammographic breast density among postmenopausal women. Presented at ASPO, Tampa, FL, March 9-10, 2009.
18. Reed SD, Buist DSM, Anderson ML, **Aiello Bowles EJ**, Fitzgibbons D, Seger D, Newton KM. Short-term (1-2 months) hormone therapy cessation before mammography. Presented at ASPO, Tampa, FL, March 9-10, 2009.
19. Sprague BL, Trenthan-Dietz A, Skinner HG, Buist DSM, Burnside ES, **Aiello Bowles EJ**, Gangnon RE, Sisney GS. The vitamin D pathway and mammographic breast density. Presented at ASPO, Washington DC, March 21-23, 2010.
20. Horner K, Wagner E, **Aiello Bowles E**, Kirlin B, Tuzzio L. The benefits of stakeholder involvement in research: experiences from our oncology nurse navigator clinical trial. Presented at HMORN, Austin, TX, March 21-24, 2010.
21. Feigelson HS, Bischoff K, Broecker K, **Bowles EA**, Engel J, James TA, Onitilo A, Single RM, McCahill L. Improving breast cancer surgery quality through a collaborative surgical database. Presented at HMORN, Austin, TX, March 21-24, 2010.
22. Sprague BL, Trenthan-Dietz A, Gangnon RE, Buist DSM, Burnside ES, **Aiello Bowles EJ**, Sisney GS. Circulating sex hormones and mammographic breast density. Presented at SER, Seattle, WA, June 23-26, 2010.
23. Romaine MA, Buist DSM, **Aiello Bowles EJ**, Anderson ML. Comparative effectiveness of reminder letters for mammography. Presented at Academy Health, Boston, MA June 27-29, 2010.
24. **Bowles EJA**, Buist DSM, Chubak J, Yu O, Boudreau DM. Uptake of tamoxifen and aromatase inhibitors in women with early stage, invasive breast cancer in a community setting, 2001-2008. Presented at American Society of Preventive Oncology annual meeting, Las Vegas, NV, March 5-8, 2011.
25. Buist DSM, **Aiello Bowles EJ**, Gao H, Brandzel S, Romaine MA, Anderson ML, Rutter C. Transition from mammogram-specific reminders to annual birthday letters for breast cancer prevention. Presented at International Cancer Screening Network Meeting, Sydney, Australia, October 23-25 2012.
26. Nyante SJ, Sherman ME, Pfeiffer RM, Berrington A, Brinton LA, **Aiello Bowles E**, Hoover RN, Glass A, Gierach GL. Patterns of longitudinal change in mammographic density among tamoxifen users. Presented at American Association of Cancer Research Frontiers in Cancer Prevention meeting, National Harbor, MD, October 27-30, 2013.
27. Brandzel S, **Bowles E**, Gao H, Wieneke A, Kimbel K, Bradford SC, Buist D. Improving response to cancer screening reminders: one size does not fit all. Presented at Academy Health annual meeting, San Diego, CA, June 8-10, 2014.
28. Larson EB, Crane PK, **Bowles EJ**, Walker R, Anderson ML, White D, Richmire K, LaCroix A, McCurry SM, Teri L, Mukherjee S, Montine TJ. The Group-Health University of Washington Adult

- Changes in Thought study: A living, learning laboratory for aging and multiple chronic conditions research. HMORN meeting, Long Beach, CA, March 11-13, 2015.
29. **Aiello Bowles EJ**, Larson EB, Pong RP, Walker RL, Anderson M, Yu O, Gray SL, Crane PK, Dublin S. Anesthesia exposure and risk of dementia and Alzheimer's disease: a prospective study. International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Boston, MA. August 22-26, 2015.
  30. Larson EB, **Bowles EJ**, Crane PK, Walker R, Anderson ML, White D, Richmire K, LaCroix A, McCurry SM, Teri L, Mukherjee S, Montine TJ. News from the Adult Changes in Thought (ACT) study: A long standing living laboratory of aging funded for five more years. HCSRN meeting, Atlanta, GA, April 13-16, 2016.
  31. Marlow EC, Langholz B, Smith-Bindman R, Kwan ML, **Bowles EJ**, Weinmann S, Miglioretti DL. Evaluating Down Syndrome as a potential confounder for pediatric CT exam exposure and leukemia risk. Radiation Research Society and Conference on Radiation and Health meeting, Hawaii, October 2016.
  32. D Miglioretti<sup>1</sup>, M Kwan, S Weinmann, **E Bowles**, W Bolch, J Duncan, L Kushi, L Yueju, E Marlow, K Theis, K Deosaransingh, M Francisco, J DeVault, M Lakoma, C Manney, J Mor, C Wong, C Jenkins, K Kumar<sup>9</sup>, C Luce, D Multerer, J Munneke, A Uchida, M Troup, R Greenlee, J Pole, A Rahm, N Stout, R Smith-Bindman. Current exposure to computed tomography imaging in US integrated health care systems. Radiation Research Society and Conference on Radiation and Health meeting, Hawaii, October 2016.
  33. **Aiello Bowles EJ**, Walker RL, Anderson ML, Dublin S, Crane PK, Larson EB. Risk of Alzheimer's disease following a cancer diagnosis. Alzheimer's Association International Conference, London, July 2017.
  34. **Aiello Bowles EJ**, Walker RL, Crane PK, Keene CD, Chubak J, Anderson ML, LaCroix AZ, Larson EB. How do we measure resilience to brain aging, dementia, and Alzheimer's disease? Alzheimer's Association International Conference, London, July 2017.
  35. Bradford SC, **Bowles E**. Less is More: Results of a HOS Improvement Study. National Quality Conference, Anaheim, CA June 2017.
  36. Brentnall AR, Cuzick J, Buist DSM, **Bowles E**. Evaluation of the Tyrer-Cuzick model of breast cancer risk with BIRADS density in a screening cohort from Washington state. 8<sup>th</sup> annual Breast Density and Cancer Risk Assessment workshop, San Francisco, CA June 2017.
  37. **Bowles EJ**, Yu O, Ziebell R, Chen L, Boudreau D, Ritzwoller DP, Hubbard R, Boggs J, Burnett-Hartman A, Sterrett A, Fujii M, Chubak J. Cardiovascular medication use and risks of colon cancer recurrences and second cancers. American Society for Preventive Oncology, New York, NY, March 2018; and Kaiser Permanente National Oncology Symposium, San Francisco, CA, April 2018.
  38. Wernli KJ, **Bowles EA**, Evans C, Gao H, Hansen K, Knerr S, Leppig K, Schwartz MD, O'Neill S. Patient characteristics associated with participation in a web-based decision support trial for women at increased breast cancer risk: ENGAGED 2 trial. American Society for Preventive Oncology, New York, NY, March 2018.
  39. **Bowles EJA**, Pole JD, Furst A, Bartels U, Kwan ML, Cheng SY, Marlow E, Greenlee R, Rahm A, Stout NK, Weinmann S, Bolch WE, Theis MK, Deosaransingh KA, Smith-Bindman R, Miglioretti DL. Trends in medical imaging use in children with central nervous system tumors. American Society for Preventive Oncology, Tampa, FL, March 2019, and Kaiser Permanente National Oncology Symposium, Los Angeles, CA, November 2019.
  40. Weinmann S, Francisco MC, **Bowles EJA**, Rahm AK, Greenlee R, Kwan ML, Smith-Bindman R, Stout NK, Pole JD, Duncan JR, Bolch WE, Kushi LH, Miglioretti DL. Positive predictive value and sensitivity of ICD-9-CM diagnosis codes for childhood leukemia in integrated health plans. Health Care Systems Research Network, Portland, OR April 2019.
  41. Kwan ML, Miglioretti DL, Marlow EC, **Aiello Bowles EJ**, Weinmann S, Cheng SY, Deosaransingh KA, Chavan P, Moy LM, Bolch WE, Duncan JR, Greenlee RT, Kushi LH, Pole JD, Rahm AK, Stout

- NK, Smith-Bindman R on behalf of the RIC study team. Trends in medical imaging during pregnancy from 1996-2016 in the United States and Ontario: The Radiation-Induced Cancers Study. Health Care Systems Research Network, Portland, OR April 2019.
42. Chen L, Chubak J, Yu O, Ziebell R, **Aiello Bowles EJ**, Fujii M, Sterrett A, Boggs J, Burnett-Hartman A, Ritzwoller DP, Hubbard RA, Boudreau D. Changes in use of opioid therapy after colon cancer diagnosis: A population-based study. Society for Epidemiologic Research, Minneapolis, MN, June 2019.
  43. Knerr S, **Bowles EA**, Wernli KJ, Schwartz MD, O'Neill S. Association between health literacy and baseline breast density awareness in a health-system embedded intervention efficacy study. American Society for Preventive Oncology, Tampa, FL, March 2019.
  44. Sun L, Brentnall A, Patel S, Buist DSM, **Bowles EJA**, Evans DGR, Eccles D, Hopper J, Li S, Southey M, Duffy S, Cuzick J, Silva IS, Miners A, Sadique Z, Yang L, Legood R, Manchada R. Unselected multi-gene testing is cost-effective in all women with a new breast cancer diagnosis vs. currently used clinical criteria or family history based testing. Kaiser Permanente National Oncology Symposium, Los Angeles, CA, November 2019.
  45. Kwan ML, Miglioretti DL, **Bowles EJ**, Weinmann S, Greenlee RT, Rahm AK, Stout NK, Moy L, Ly D, Fong C, Luce C, Kohnhorst D, Martinez YS, Munneke JR, Prado JR, Alber SA, Buth G, Deosaransingh KA, Francisco M, Lau C, Mor JM, Theis MK, Kushi LH, Duncan JR, Kolfer CM, Bolch WE, Pole JD, Smith-Bindman R. Medical radiation exposure and childhood cancer risk in the United States and Ontario, Canada: the Radiation-Induced Cancers (RIC) Study. International Society of Radiation Epidemiology & Dosimetry, 2020, *cancelled due to COVID-19 pandemic*.
  46. Smith-Bindman R, Kwan ML, Alber S, Bolch WE, **Bowles EJ**, Duncan JR, Furst A, Greenlee R, Kolfer C, Lau C, Pole JD, Stout NK, Weinmann S, Ly D, Moy L, Miglioretti DL. Risk of pediatric and adolescent leukemia associated with medical imaging. International Society of Radiation Epidemiology & Dosimetry, 2020, *cancelled due to COVID-19 pandemic*.
  47. DeVange S, MacDonald L, Hillier M, Jhampatong N, **Bowles E**, Tuzzio L, Leppig K. A new genetic testing model for women at high risk for breast cancer based on family history. American College of Medical Genetics, 2020, *cancelled due to COVID-19 pandemic*.
  48. Wernli KJ, Knerr S, Li T, Leppig K, Ehrlich K, Farrell D, Gao H, **Bowles EJA**, Graham AL, Luta G, Mandelblatt JS, Schwartz MD, O'Neill SC. Randomized trial of a web-based personalized breast cancer risk communication and decision support tool on clinical prevention outcomes. American Society for Preventive Oncology, 2020, *cancelled due to COVID-19 pandemic*.
  49. Haas C, **Bowles E**, Lee J, Specht J, Buist D. Accuracy of tumor registry data for capturing endocrine therapy treatment compared to pharmacy data among women with breast cancer from an integrated healthcare delivery system. Health Care Systems Research Network, virtual, May 2021.
  50. **Bowles EJA**, Ramin C, Buist DSM, Feigelson HS, Weinmann S, Veiga L, Bodelon C, Curtis RE, Vo JB, Berrington de Gonzalez A, Gierach. Endocrine therapy initiation within the first year of diagnosis for invasive, hormone receptor-positive breast cancer from 2001-2016, the Kaiser Permanente Breast Cancer Survivors' Cohort. American Society for Preventive Oncology, Tucson, AZ, March 2022.
  51. R Smith-Bindman, M Kwan, Y Li, S Alber, C Kofler, WE Bolch, JD Pole, P Pequeno, **EJ Bowles**, R Greenlee, S Weinmann, L Moy, D Miglioretti. Radiation Dose Associated with Common CT Examinations Over Time in the US and Ontario Canada, International Society of Radiation Epidemiology and Dosimetry meeting in May, 2023
  52. DL Miglioretti, ML Kwan, Y Li, S Alber, P Pequeno, T Tran, C Kofler, WE Bolch, **EJ Bowles**, R Greenlee, JD Pole, S Weinmann, L Moy, R Smith-Bindman. Imaging Utilization in Preterm Infants and Associated Radiation Exposure and Cancer Risk, International Society of Radiation Epidemiology and Dosimetry meeting in May, 2023
  53. Kantor ED, O'Connell KO, Ergas IJ, Valice E, Roh JM, Bhimani J, Heon N, Griggs JJ, Lee J, **Bowles EJA**, Rivera DR, Kolevska T, Bandera EV, Kushi LH. Assessment of Breast Cancer Chemotherapy

- Dose Reduction in an Integrated Healthcare Delivery System. San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-10, 2022.
54. Bhimani J, O'Connell KO, Burganowski RP, Ergas IJ, Foley MJ, Gallagher GB, Griggs JJ, Heon N, Kolevska T, Kotsurovsky Y, Kroenke CH, Nakata KG, Persaud S, Rivera DR, Roh JM, Tabatabai S, Valice E, **Bowles EJA**, Bandera EV, Kushi LH, Kantor ED. A methodology for using real-world data from electronic health records to assess chemotherapy administration in women with breast cancer. San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-10, 2022.
  55. Foster VM, Trentham-Dietz A, Stout N, Lee CI, Ichikawa LE, Eavey J, Henderson L, Miglioretti DL, Tosteson A, **Bowles E**, Kerlikowske K, Sprague BL. Supplemental screening for breast cancer after negative mammography in U.S. women with dense breasts. International Breast Density Workshop, Kailua-Kona, HI, June 2023.
  56. Abubakar M, MULLOOLY M, Nyante S, Pfeifer RM, **Aiello Bowles EJ**, Weinmann S, Sherman M, Vo JB, Berrington de Gonzalez A, Gierach GL. Stromal disruption of histologic sections impairs tamoxifen associated mammographic density reduction and portends poor prognosis in estrogen receptor-positive breast cancer. International Breast Density Workshop, Kailua-Kona, HI, June 2023.
  57. Davies L, Fernandes-Taylor S, Arroyo N, Zhang Y, **Bowles E**, Alagoz O, Francis DO. Optimizing face validity and clinical relevance of the first cross-population microsimulation model to represent papillary thyroid carcinoma epidemiology in the United States using a novel stakeholder advisory group approach. American Thyroid Association annual meeting, Washington DC, Sept 2023.
  58. Alagoz O, Zhang Y, Arroyo E, Fernandes-Taylor S, Yang DY, Venkatesh M, Hsiao V, **Bowles E**, Davies L, Francis DO. The development of the first cross-population microsimulation model to represent papillary thyroid carcinoma epidemiology in the United States. American Thyroid Association annual meeting, Washington DC, Sept 2023.
  59. Fernandes-Taylor S, **Bowles E**, Venkatesh M, Doud R, Krebsbach C, Arroyo N, Hanlon B, Davies L, Alagoz O, Francis DO. Sex disparities in thyroid cancer incidence are driven by differential ultrasound rates. American Thyroid Association annual meeting, Washington DC, Sept 2023.
  60. Bhimani J, O'Connell KO, Burganowski RP, Ergas IJ, Foley MJ, Gallagher GB, Griggs JJ, Kolevska T, Kotsurovsky Y, Kroenke CH, Nakata KG, Persaud S, Roh JM, Tabatabai S, Valice E, **Bowles EJA**, Bandera EV, Kushi LH, Kantor ED. The evolving landscape of chemotherapy for the treatment of early-stage breast cancer from 2006-2019: results of a retrospective cohort study. ASCO Quality Care Symposium, Boston, MA, October 27-28, 2023.
  61. **Bowles EJA**, Ramin C, Feigelson HS, Gander JC, Veiga LHS, Bodelon C, Curtis RE, Brandt C, Vo JB, Berrington de Gonzalez A, Gierach G. Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ breast cancer from 2001-2018. ASCO Quality Care Symposium, Boston, MA, October 27-28, 2023.
  62. Foster VM, Trentham-Dietz A, Stout NK, Lee CI, Ichikawa LE, Eavey J, Henderson L, Miglioretti DL, Tosteson ANA, **Bowles EA**, Kerlikowske K, Sprague BL. Breast density notification laws: impact on supplemental breast cancer screening. American Society of Preventive Oncology, Chicago, IL, March 13-15, 2024.
  63. **Bowles EJA**, Nash M, Bravo P, Comstock B, Fleckenstein L, Schartz E, Gao H, Pflugeisen C, Smith C, Shetty P, Ornelas I, Neslund-Dudas C, Mou J, Kessler L. Validity and reliability of National Health Interview Survey questions on cancer screening. American Society of Preventive Oncology, Chicago, IL, March 13-15, 2024.
  64. **Aiello Bowles EJ**, Bhimani J, O'Connell K, Gallagher GB, Blinder VS, Doud RP, Griggs JJ, Kolevska T, Kroenke C, Laurent C, Liu R, Nakata KG, Persaud S, Rivera D, Roh JM, Wang P, Bandera EV, Kushi LH, Kantor E. Associations between age at diagnosis and chemotherapy dose reductions in women treated for stage I-IIIa breast cancer. ASCO Quality Care Symposium, San Francisco, CA, September 27-28, 2024.

65. Kantor E, O'Connell K, Bhimani J, Blinder VS, Doud RP, Gallagher GB, Griggs JJ, Kolevska T, Kroenke C, Laurent C, Liu R, Nakata KG, Persaud S, Rivera D, Roh JM, Valice E, Wang P, Bandera EV, **Aiello Bowles EJ**, Kushi LH. Provider and facility factors in relation to receipt of dose-reduced chemotherapy among patients with breast cancer. ASCO Quality Care Symposium, San Francisco, CA, September 27-28, 2024.
66. Veiga LHS, Vo JB, Curtis RE, Smith S, Howell R, Mille MM, Ramin C, Bodelon C, **Aiello Bowles EJ**, Buist DSM, Weinmann S, Feigelson HS, Gierach GL, Lee C, Berrington de Gonzalez A. Risk of subsequent contralateral breast cancer after radiotherapy and hormonal therapy in two cohorts of US breast cancer survivors. Cancer Prevention Research Conference, Boston, MA, June 25-27, 2024.
67. **Aiello Bowles EJ**, Zakaria Z, O'Connell K, Bhimani J, Gallagher GB, Doud RB, Griggs JJ, Kroenke CH, Laurent C, Lio R, Nakata KG, Roh JM, Wang P, Bandera EV, Kushi LH, Kantor ED. Associations between demographic and tumor characteristics with chemotherapy dose reductions in women treated for stage I-III breast cancer. American Society of Preventive Oncology annual meeting, Philadelphia, PA, April 6-8, 2025.
68. Iglesias MM, O'Connell K, Bhimani J, Blinder V, Doud R, Gallagher G, Griggs J, Kolevska T, Kroenke C, Laurent C, Liu R, Nakata K, Roh J, Sampathkumar Y, Valice E, Wang P, **Bowles E**, Bandera E, Kushi L, Kantor E. Impact of initial chemotherapy dosing on subsequent dosing patterns and treatment completion in early-stage breast cancer. American Society of Clinical Oncology annual meeting, May 30-June 3, 2025, Chicago, IL.
69. Kantor E, O'Connell K, Bhimani J, Blinder V, Doud R, Gallagher G, Griggs J, Monroy-Iglesias M, Kolevska T, Kroenke C, Laurent C, Liu R, Nakata K, Roh J, Sampathkumar Y, Valice E, Wang P, Bandera E, **Bowles E**, Kushi L. Obesity, chemotherapy dosing, and toxicity: results from the Optimal Breast Cancer Chemotherapy Dosing study. American Society of Clinical Oncology annual meeting, May 30-June 3, 2025, Chicago, IL.
70. Hurson AN, Veiga LHS, Bodelon C, Curtis RE, **Aiello Bowles EJ**, Feigelson HS, White L, Honda S, Ryerson BB, Mullooly M, Vo J, Berrington de Gonzalez A, Gierach GL. Investigating the impact of radiotherapy and endocrine therapy on mammographic breast density changes in the contralateral breast of breast cancer survivors. International Breast Density and Cancer Risk Assessment Workshop, June 4-6, 2025, Lihue, HI.